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Preface
This dissertation is the presented works of 5 interdependent chapters, three of which are
published in journals and two in preparation for publication. The contributions of each
body of work will be explained rigorously in this section. In all works, Dr. Jeremy
Goldman and Dr. Jaroslaw Drelich provided guidance, editing, and final approval of the
manuscript. Dr. Jeremy Goldman conducted most surgical in vivo implantations.
The first chapter investigates first-generation zinc materials and relates host inflammatory
reaction to corrosion characteristics. It is under the full citation:
1. Guillory, Roger J., Patrick K. Bowen, Sean P. Hopkins, Emily R. Shearier, Elisha J. Earley,
Amani A. Gillette, Eli Aghion, Martin Bocks, Jaroslaw W. Drelich, and Jeremy Goldman.
"Corrosion characteristics dictate the long-term inflammatory profile of degradable zinc arterial
implants." ACS Biomaterials Science & Engineering 2, no. 12 (2016): 2355-2364.

The experimental design, execution, writing, and data analysis was mostly performed by
Roger J. Guillory II. Dr. Patrick Bowen contributed to SEM and backscattered electron
imaging of the implants, and writing/editing sections of the manuscript. Dr. Sean P.
Hopkins contributed to data analysis of the macrophage staining and writing. The other
co-authors contributed to histological staining procedures and final review of the
manuscript.
The second chapter discusses the development of a novel preclinical model to screen
degradable metal candidates for cardiovascular stents. The full citation is provided below:
2. Guillory, Roger J., Alexander A. Oliver, Emma K. Davis, Elisha J. Earley, Jaroslaw W.
Drelich, and Jeremy Goldman. "Preclinical In Vivo Evaluation and Screening of ZincBased Degradable Metals for Endovascular Stents." JOM 71, no. 4 (2019): 1436-1446.

The design, execution and data analysis were primarily performed by Roger J. Guillory.
Roger J. Guillory wrote the entire manuscript, and all authors contributed to revisions
prior to final publication. Emma k. Davis created one of the 7 figures in the manuscript,
and Alexander Oliver and Elisha Earley helped with histological sectioning and staining.
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The third chapter investigates the relationship between the surface of degradable zinc
materials and the subsequent vascular response, using the model described in the second
chapter. The full citation is provided below:
3. Guillory II, Roger John, Malgorzata Sikora-Jasinska, Jaroslaw W. Drelich, and Jeremy
Goldman. "In Vitro Corrosion and In Vivo Response to Zinc Implants with Electropolished
and Anodized Surfaces." ACS applied materials & interfaces(2019).

Roger J. Guillory designed the experiments, performed all histology and sectioning, and
processed all in-vivo data. Dr. Malgortza Sikora-Jasinska performed all in vitro corrosion
experiments, with both authors developing the surface treatments used throughout the
study. XPS was performed by Dr. Timothy Leftwhich, with sample preparation
performed by Roger J. Guillory and Dr. Malgorzata Sikora-Jasinska. Dr. Malgorzata
Sikora-Jasinska participated in writing sections of the manuscript and prepared 2 figures
fully and one figure jointly. Roger J. Guillory wrote most of the manuscript and prepared
2 figures fully, and one figure jointly.
The fourth chapter describes the newest generation of zinc-based materials developed by
our research group. This chapter is in preparation to be submitted to an academic journal.
Roger J. Guillory designed the experiments, performed data analysis and wrote the entire
manuscript. Dr. Ehsan Mostaed developed the novel material and produced wires from
castings. Roger J. Guillory constructed the figures, with the exception of the TEM figure
produced by Dr. Ali Mostaed, which was made by Dr. Ehsan Mostaed. The other coauthors participated in histological staining and data collection.
The last chapter investigates an exciting phenomenon seen at the interface of zinc-based
materials in the vascular environment. This work is in preparation to be submitted to an
academic journal. Roger J. Guillory designed the experiments and performed histological
processing, enzymatic assays, data analysis, constructed figures, and wrote the entire
manuscript. Alexander Oliver participated in histological data collection and analysis.
Timothy Kolesar and Lea Morath performed enzyme activity assays and histological
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staining. Dr. Malgorzata-Sikora Jasinsaka performed ICP analysis from in vitro corrosion
studies.
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Abstract
Biodegradable stents based on zinc have been under development since their introduction
in 2013. While metallic zinc is highly ductile, it unfortunately lacks the mechanical
strength required for arterial stents. This has led to the development of an abundance of
novel zinc-based materials, with the aim of improving the mechanical strength without
sacrificing too much ductility. Although these materials are intended to function and
slowly degrade within an artery, most zinc-based materials have been developed without
deep consideration for their biological effects.
The present work explores the biological effects elicited by zinc-based materials
implanted within the arterial system. The biological effects of degradable arterial
implants were characterized in terms of quantifiable metrics, including neointimal area,
implant to lumen thickness, and base neointimal length. These metrics were used to
clarify relationships between material characteristics, including surface oxide film
stability, elemental composition, and microstructure, with biological responses. The
metrics were also used to compare materials in terms of their biocompatibility. In
addition to evaluating biocompatibility, beneficial elements identified by these
approaches can be further investigated for their therapeutic value, since all the elements
in the implant will be released due to implant degradation. The combined work makes it
possible to screen materials in terms of their biocompatibility and provides fundamental
insights that impact the metallurgical design of materials.
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Introduction
1.2 Heart disease and the state of the art
Heart disease poses an extreme health and monetary risk for Americans. According
to the most recent update by the American Heart Association (2017), 92.1 million US
adults have at least one type of cardiovascular disease. The average annual cost from
heart disease to Americans in 2013 was 199.6 billion USD. Additionally, myocardial
infarction and coronary heart disease were 2 of the 10 most expensive hospital
diagnoses[1]. The most predominant underlying pathology of myocardial infarction
is atherosclerosis. Atherosclerosis is a complex, progressive disease characterized by
events such as lipid deposition, intra-arterial plaque formation and buildup,
inflammatory mediation and subsequent thrombogenic events emanating from
unstable ruptured plaques, all of which contribute to luminal obstruction[2-4].
Presently, the gold standard for treatment of atherosclerosis-induced arterial stenosis
is balloon catheter stenting. These metal scaffolds increase the cross-sectional area of
the arterial lumen, enhancing downstream blood flow to vital organs (e.g. heart or
brain). While the early term effects of stenting diseased arteries are generally positive,
the permanent residence of the metal scaffold within the vasculature elicits chronic
negative effects. These deleterious effects can include smooth muscle cell intimal
hyperplasia due to persistent inflammation[4], stent thrombosis[5], and de novo
neoartherosclerosis[2, 6-8].
Over the past 15 years, advances within the interventional cardiology sector have
aimed to mitigate early negative outcomes with paclitaxel and sirolimus polymer
loaded drug eluting stents[9] (DES), which successfully reduce restenosis rates
compared to bare metal stents[10]. Although first generation DESs were effective
initially, delayed healing/ endothelialization and an increased risk of very late stent
thrombosis have plagued first generation DESs[11]. Second generation everolimus
DESs are superior to first generation DESs[10], yet still succumb to
14

neoatherosclerosis after a long term residence, which appears to be an end term
failure mode of any implanted stent regardless of drug elution[7].

1.3 Degradable stents
1.3.1 Polymeric scaffolds
Inadequate mitigation of negative long-term permanent stent outcomes has generated
an intense interest for exploring alternative solutions. The most promising alternative
approach is to develop a stent that is completely and safely absorbed over time by
local vascular tissue. This concept was pioneered by Tami et al, who deployed 25
poly-L-lactic acid stents in 19 lesions across 15 patients with a 6 month follow up
time. The study concluded that no significant progressive intimal hyperplasia or
lumen loss over 3 and 6 months were provoked by the degradable PLLA based
stents[12]. A ten year follow up of the Igaki- Tami stents proved the efficacy of a
degradable stent, with mean complete degradation of around 3 years[13]. The 2014
Absorb trials of fully degradable PLLA- everolimus eluting stents showcased the
efficacy of drug eluting degradable stents[14]. Although the success of degradable
polymeric materials has been clearly shown, this class of materials cannot feasibly
achieve the mechanical benchmarks required for arterial stents. This inherent
limitation restricts polymeric materials to treating simple lesions of short length.
Additionally, the lower radial strength of polymers increases the chances of acute
stent recoil and strut malapposition and necessitates an enlarged polymer strut
thickness. The excessive strut size and surface area increases arterial injury and
thrombogenesis. These serious limitations argue for a degradable metallic alternative.
1.3.2 Degradable metals
Iron
Peuster and others were some of the first pioneers to investigate iron as a potential
degradable metallic stent material [15]. They investigated the efficacy of 16 iron stents in
15

the descending aorta of New Zealand white rabbits. While these stents performed well
with no apparent toxicity and inflammatory response, they did not investigate the ability
of the stent to fully corrode. A long term (12 month) follow up study by the authors
determined that there was a need to increase the degradation rate of iron materials, as
most of the stent remained after the 1 year follow up period [16]. Many investigations
after these landmark studies focused on modifications of the bulk iron material to
increase the degradation rate [17-25]. More recent absorbable metal candidates have
overtaken the use of iron as a base material.
Magnesium
The most obvious degradable metal candidate, and perhaps the most successful have been
materials with a base composition of magnesium. An early study by Heublein and
colleagues demonstrated the feasibility of using a non commercial magnesium based
alloy to serve as a degradable scaffold, in swine[26]. This initial success for magnesium
generated excitement within the degradable metals field, prompting implantations of fully
degradable magnesium stents in newborns to treat congenital heart defects, with some
degree of success[27, 28]. Unfortunately, the corrosion of magnesium suffers from
excessive degradation rates, which is the opposite problem of iron-based materials. With
corrosion rates between 19-44 mg/cm2/day, it was estimated that a 5g magnesium implant
would lose functionality in 10-20 days, and be completely dissolved within 20-45
days[29]. Magnesium is also known to generate hydrogen gas through the following
reaction;
Mg+2H2O⇄Mg2++H2+2OH-

(1)

Since magnesium degradation generates around 1L of H2 per gram of pure material,
processing and alloying approaches have received an intense focus from engineers
intending to slow the degradation rate of magnesium. A lower degradation rate would be
beneficial from an arterial healing standpoint and serve to reduce the rate of potentially
16

damaging hydrogen gas evolution [30-32]. Although these challenges have precluded the
translation of degradable magnesium into safe and effective arterial stents, magnesium
still remains the most successful degradable metal material in terms of commercialization
progression. A number of clinical trials have demonstrated the efficacy of metal-based
degradable stents, including the DREAMS 2G (MAGMARIS) BIOSOLVE II and
BIOSOLVE III [33, 34]. Although there has been some success with Mg based scaffolds,
problems include mechanical properties that do not yet approach that of conventional
metal stents, yielding large strut sizes[35]. Another critical limitation of Mg based stents
is the need for a drug eluting coating, which is a known contributor to late term stent
thrombosis and delayed endothelialization[36]. Finally, despite extensive metallurgical
modifications reported in the literature, Mg stents still degrade too rapidly (<12 months)
to support the proper healing of diseased vasculature[35].
Zinc
Bowen and colleagues introduced zinc in 2013 as a promising degradable metal candidate
for coronary stenting[37]. With a penetration rate near the proposed benchmark of 20
µm/ year, along with compact corrosion products, zinc materials quickly became a
favored candidate for degradable metallic stents[38]. As with the other two degradable
metal candidates, the potential upsides come with substantial limitations.
Pure zinc does not possess adequate mechanical properties for stenting, with a tensile
strength around 120 MPa, although it has a rather pronounced elongation to failure of
60%-80%[38]. Stenting materials should possess mechanical properties that are
approximated in the table below.
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Table 1. Mechanical characteristics of Zn compared to stent material benchmark values
Mechanical Properties
Metal

Benchmark

Yield

Tensile

Elongation

Grain

Strength

Strength

to Failure

Size

[MPa]

[MPa]

[%]

>200

>300

>15

<30

<80

<120

60 - 80

>50 -

[m]

Value
Pure Zn
(reference)

100

With the introduction of zinc in 2013, questions surfaced regarding the biocompatibility
of the metal. Bowen et. al. demonstrated the exceptional biocompatibility of pure zinc
within the abdominal aorta of rats[39], using a wire implantation model developed by
Pierson et. al. in 2012[40]. Zinc provoked relatively small neointima formations, with an
notable gradient of smooth muscle cells receding towards the implant[39]. With the
introduction of zinc materials and their optimal biocompatibility, a new wave of material
development from metallurgists began to improve the mechanical properties through
elemental additions and advanced processing [41-55].

1.4 Scope of dissertation
The excitement generated in the field of degradable Zn based stents led to a bottleneck of
novel materials that required biocompatibility evaluations. The in vivo evaluation of
degradable materials required a shift in the framework of modern biomaterials
development and testing. Our group at Michigan Tech first developed an in-vivo “wire
model” to simplify the characterization of the host response to degradable materials
18

intended for use as cardiovascular stents[40]. This model provides a unique platform to
study degradable materials in a fashion that allows detailed examination of the tissue material interaction. In order to develop successful zinc-based materials, a thorough
understanding of the material-arterial cell interactions and the resulting biologic response
is essential. We outline these new approaches and investigations in the chapters of this
dissertation.
1.4.1 Chapter 1
This chapter investigates multiple zinc materials in an arterial wall implant model. The
wall implant model was chosen initially as a simplified environment relative to the
luminal space due to the avoidance of blood interaction. This work begins to clarify the
relationship between material corrosion character and the ensuing host response.
Classically, the foreign body response is a progressive reaction to an implanted
biomaterial that eventually leads to fibrotic encapsulation. This classic understanding of
the biological response to implanted materials, although widely accepted, must be
adapted to incorporate the dynamic and complex biointeractive properties of degradable
materials. Understanding the contribution of corrosion products and behavior to the
vascular response and overall biocompatibility is of critical importance when designing
biodegradable materials.
1.4.2 Chapter 2
Alloying of degradable zinc materials has become a standard approach to improve the
mechanical properties. The primary evaluation of materials is a straightforward
mechanical testing to compare novel materials to stent material benchmark values. When
biocompatibility is evaluated, the primary start point is an insult of corrosion media
supernatant extract to 2-D cultured cells. This approach, while useful for understanding
basic toxicity, is not appropriate to clarify the in vivo performance of degradable metals.
To clarify the biocompatibility of a degradable material, a realistic application
environment is an essential start point. Here we develop a quantitative, engineering based
19

approach to evaluate the performance of degradable materials in an in-vivo system. This
approach, while possessing both strengths and weaknesses, can nevertheless help identify
the best performing materials using a low cost, physiologically relevant animal model.
1.4.3 Chapter 3
A critical component of material design, particularly in metals that will eventually
degrade, are the surface features. Long-term material corrosion characteristics of zinc
materials can be directed by the material’s initial surface conditions. Since the potential
exists for the control of surface properties to make possible the “tunability” of corrosion
dynamics, the relationship of surface characteristics to the vascular response must be
clarified. This chapter describes an investigation to relate varied surface features of
degradable zinc-based implants to the vascular response.
1.4.4 Chapter 4
Our group at Michigan tech has steadily developed a suite of degradable metal candidates
for cardiovascular stents. Previously, it has been challenging to relate differences in
neointimal character to specific modifications of materials. This chapter evaluates a new
generation of degradable zinc alloys and provides insight into the relationship between
elemental compositions and neointimal formation. Understanding the interplay between
metallic elemental additions and vascular responses is critical to designing top
performing alloys. In parallel, we have also discovered that changes to the microstructure
affect neointimal responses. These two components of alloy design not only alter the
mechanical properties of materials, but also critically impact biological outcomes.
1.4.5 Chapter 5
To date, we have examined zinc materials from a performance standpoint in order to
select the best performing materials for continuation in the stent development pipeline.
While this approach is useful from an engineering and commercialization standpoint,
there is tremendous value in understanding the basic interactions between the material
20

and arterial cells. Recently, Bowen and colleagues described an exciting phenomenon of
neointimal smooth muscle cells organizing peripherally from the degradable zinc implant
and avoiding the interface. In this contribution, the neointima of pure zinc materials is
probed for smooth muscle cell content and compared to a non-degrading control.
Molecules involved with the regulation and initiation of apoptosis are monitored. A
material that can exert an anti-proliferative/pro-apoptotic effect on the migratory smooth
muscle cells is ideal within the realm of vascular materials. Current generation stents
require a drug eluting polymer coating to prevent excessive neointimal growth and limit
harmful outcomes. Here, we find that the byproducts of zinc implant degradation may
impart a suppressive effect against vascular smooth muscle cells and anti-inflammatory
pro-healing effects on endothelial cells. This paradigm shift that emerges with degradable
zinc materials within the vasculature may shift the way scientists think about degradation
as a whole; not just as a peripheral feature of the material, but as central means of
imparting continuous therapy to the treated vessel for the entire lifetime of the implant.

1.5 Summary
This dissertation provides new insights into the biocompatibility of degradable zinc
implants for use in the cardiovascular system. Chapter 1 provides a rigorous and detailed
histopathological analysis of zinc and zinc alloys in an in vivo implant model. The
methodology used allows for a multifaceted approach to understanding the dynamic
foreign body response to degrading materials. From this work, we are able to determine
that the inflammatory response not only depends on the elemental additions, but
manifests primarily from the inherent corrosion characteristics dictated by the elemental
additions. These results demonstrate that tissue reactions towards degrading zinc
materials can be regulated by controlling corrosion behavior.
With this newfound knowledge, a natural hypothesis arises that different degradable zinc
materials (ie. Zn-Li vs. Zn-Mg) with different inherent corrosion properties will evoke
different responses in the vascular system. To test this hypothesis, an analysis framework
with appropriate design and outcome metrics needs to be established. Chapter 2
21

accomplishes this by developing a reliable method for the quantification of
biocompatibility metrics within the rodent aorta. This standardized methodology makes it
possible to compare materials in terms of biocompatibility and relate the differences in
biocompatibility of materials to material characteristics. By using histomorphometry
parameters that are similar to those used when evaluating stents in the clinic, the results
from the characterization of neointimal responses to wire implants can be compared to
stents that are in clinical use.
Since it is apparent that corrosion characteristics affect neointimal growth and
development, variations in the initiation of corrosion would be expected to dramatically
alter the vascular response. In chapter 3 we vary the surface oxide film character of pure
Zn substrates to investigate the effect of surface oxide film properties on early term
neointimal responses. Interestingly, standard surface treatments used for permanent
metallic materials may not be optimal for zinc implants. This is due to the initiation of
harmful corrosion events that exacerbate neointimal progression when using zinc
implants with electropolished surfaces.
Chapter 4 probes deeper into the neointimal responses of a wide variety of new
generation alloys, using the established framework presented in Chapter 2. Complex
alloy systems (elemental additions >3) provide unique changes at a microstructural level,
which are found to directly impact the neointimal response/ performance of the material.
Understanding the relationship between the microstructure and neointimal response
provides predictive power that aids in the design of future materials.
Even though this body of work rigorously demonstrates that bulk corrosion, surface
characteristics, and microstructural changes in Zn materials impact biocompatibility, the
role of the corrosion byproducts in the biocompatibility of the implant remains a critical
open question. Chapter 5 probes the cellular and protein content in the neointimal tissue
surrounding Zn based implants. The results of the analyses demonstrate that ionic Zn
initiates apoptotic death in vascular smooth muscle cells. Importantly, this chapter shows
that metallic zinc may serve not only as structural support for the vessel, but its release in
22

an ionic form profoundly affects neointimal cells through its interaction with proteinmediated cell signaling pathways.
Together, this body of work evaluates the impact of zinc-based materials as potential
cardiovascular stents on biocompatibility by integrating a large spectrum of fields
ranging from materials science, physiology, and cell and molecular biology. During the
course of this multifaceted investigation, novel approaches are developed and material
properties are related to neointimal growth and device performance.
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1 Understanding zinc material corrosion characteristics
and the foreign body response progression in the
arterial environment 1 2
1.1 Introduction
The concept of constructing fully bioresorbable stents (BRSs) to open occluded arteries
using non-toxic degradable materials has inspired extensive research over the past two
decades, with an emphasis placed on polymer-based materials 1. While multiple polymerbased fully degradable BRS have proceeded through early clinical trials in the US and are
beginning to obtain FDA approval2, the development of stents manufactured from
metallic materials has largely been restricted to pre-clinical studies 1b. This has been the
case despite the order-of-magnitude mechanical strength advantage that metals derive
over polymers and their similarity to conventional stents in terms of deployment and
mechanical characteristics.
Magnesium has been extensively investigated for endovascular stenting and is the only
biometallic stent studied in the clinical setting. The benefits of magnesium-based stents
include low thrombogenicity, excellent biocompatibility to neighboring cells and tissue,
and good target lesion failure rates at 6 months, especially when coated with an
antiproliferative drug 3. However, early generation magnesium stents were found to have
high degradation rates and even the 2nd generation stents have late lumen loss rates much
higher than standard DESs and some of the polymer-based BRSs 4. Though studied less
in recent years, iron-based materials have the favorable profile of producing low to
moderate inflammatory responses and possess excellent mechanical properties 5, but
produce voluminous corrosion products that build up in the artery and repel neighboring
cells and biological matrices 6. The serious limitations of iron and magnesium and the
intense focus on surmounting them with incremental material modifications have delayed

1
2
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developmental efforts for bioabsorbable metallic stents relative to polymers. Recently,
zinc and its alloys were introduced as stent materials that do not experience the
limitations seen with iron and magnesium7. Zinc could potentially break through the
considerable developmental hurdles facing absorbable biometals (for a recent review of
zinc and its progress towards becoming a candidate material for endovascular stents, refer
to 1b).
In contrast to an inflammatory response generated around a biostable material, which is
directed primarily against the base material—metals and their stable oxide layer in the
case of bare metal stents, or polymers in drug-eluting variants—the inflammatory
response to a corrodible metal may also be impacted by the corrosion behavior and the
products thereby generated. To date, most studies have focused on the in vitro
degradation and cytotoxicity of zinc and zinc alloys 8. With the exception of limited-inscope in vivo work performed by our group 1b, 7, 9, a detailed investigation into the cellular
and tissue interactions with metallic based corrosion products for a degradable metal
remains largely unexplored 1b. Due to the complex biochemical and cellular constituents
present in the physiological environment that impact the generation and progression of
corrosion products, as well as their integration and ultimate break down and clearance, a
long-term in vivo evaluation is essential to clarify the biological response.
The present work was undertaken to characterize the chronic inflammatory response to
zinc by drawing detailed comparisons between different zinc-based materials displaying a
range of corrosion behaviors. We describe the cell/tissue remodeling events that take
place on the active tissue-material interface of degrading zinc implants in order to
understand the inflammatory progression. Through a direct comparison it may be
possible to gauge the inflammation response severity and clarify how corrosion behavior
may regulate inflammatory pathways. This type of analysis may eventually allow for an
improved design of zinc-based stent materials with the goal of minimizing the severity of
chronic inflammatory responses.
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1.2 Experimental
1.2.1 Materials and reagents
0.25 mm diameter wire of 99.99+ wt.% (4N) zinc was purchased from Goodfellow
Corporation. Zn-Al alloy ingots were purchased from Metropolitan Alloy Co. (Detroit,
MI) at concentrations of 0, 1, 3, and 5.5 wt. % Al. The Zn stock used for fabrication was
special high grade (SHG) ~99.7% zinc per ASTM B6-13. Ingots were gravity cast, in air,
into flat steel molds. The pancake ingots received measured approximately 100  70 
10 mm. Alloying with aluminum substantially improved the mechanical properties of the
zinc material (the detailed microstructure and mechanical properties characterization are
included in a separate contribution10). Table 1-1 provides the list of impurities and their
concentrations in both 4N and SHG Zn.
Table 1-1 – Impurity levels in 4N and SHG Zn
Concentration (ppm)
Impurity
4Na
SHGb
Ag
5
<2
Al
n/s
<2
As
n/s
<2
Cd
7
<2
Cu
5
7
Fe
25
371
Mg
n/s
<2
Mn
<1
3
Pb
15
16
Si
< 1 n/a

a

Per specification; non-specified impurities are labeled
“n/s”
b
Measured via inductively coupled plasma optical
emission spectroscopy; non-analyzed impurities are
labeled “n/a”
Electro-discharge machining was used to fabricate SHG and Zn-Al strips measuring
approximately 12 mm long × 300 µm wide × 300 µm thick from the rolled foil. The
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strips were electropolished using a stirred bath of 120 mL deionized water, 885 mL ethyl
alcohol (200-proof – Pharmco Aaaper, Brookfield, CT), 100 mL n-butyl alcohol (99.9% Fisher Scientific, Fair Lawn, NJ), 250 g anhydrous zinc chloride (reagent grade –
Avantor, Center Valley, PA), and 109 g aluminum trichloride hexahydrate (97+% Sigma Aldrich, St. Louis, MO) at a constant potential of 10 V for 90 seconds 11. Due to
the electropolishing, the thickness of strips was reduced to 220-270 µm and their
rectangular cross-sectional dimension aligned closely with that of a wire and are hereafter
referred to as wires.
Staining reagents included eosin Y disodium salt, acetic acid (99.7%), toluidine blue
(powdered), phosphotungstic acid solution 10% w/v, phosphomolybdic acid hydrate
solution, biebrich scarlet acid-fuchsin solution, analine blue solution, absolute ethanol,
xylene substitute, Gill’s No. 3 hematoxylin solution, hematoxylin (powdered), anhydrous
iron (III) chloride (powder 99.99%), Lugol’s iodine Solution phosphate buffered saline
(PBS),phosphate buffered saline with bovine serum albumin (PBS-BSA), and Eukitt
quick-hardening mounting medium; all were obtained from Sigma Aldrich. Hydrochloric
acid (HCl) (37%; 12.2 M) was obtained from EMPROVE (Darmstadt, Germany).
Reagent grade acetone was obtained from Pharmco-Aaper.
Primary antibodies included anti-CDd68 (ab125212), anti-Cd11b (ab8879) all purchased
from Abcam (Cambridge, Massachussetts). Secondary antibodies include goat anti-rabbit
IgG alexa fluor 488 (ab150077), donkey anti-rabbit IgG alexa fluor 555 (ab150074)
purchased from Abcam, and anti-CD163 (sc-58965) purchased from Santa Cruz
Biotechnology (Dallas, Texas). Streptavidin alexa fluor 633 conjugate (S-21375) was
purchased from Life Technologies (Carlsbad, California). Biotinylated goat anti rabbit
IgG (ab64256), biotinylated goat anti mouse IgG, and endogenous avidin/biotin blocking
kit (ab64212) were all purchased from Abcam. Goat serum (G9023), 4′, 6-diamidino-2phenylindole dihydrochloride (DAPI), Triton X-100, phosphate buffered saline (pH 7.4
containing 1% BSA w/v) were all purchased from Sigma-Aldrich. PermaFluor mountant
was purchased from Thermo-Scientific (Waltham, Massachussetts).
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1.2.2 In vivo implantation and cryo-sectioning
The zinc implant wires including 4N, SHG, Zn-1Al, Zn-3Al, and Zn-5Al were cleaned in
acetone and then sterilized in 70% (v/v) ethyl alcohol for 20 to 30 min prior to
implantation. A surgical protocol developed recently was employed to implant two wires
of the same material composition into the abdominal aorta wall of an adult SpragueDawley rat 6. Briefly, the wires were used to penetrate the adventitial layer of the
abdominal aorta, after which the wire was advanced within the arterial wall for the full
length of the specimen. We have found that the wall environment is more conducive to
biocorrosion activity whereas blood contact from a luminal implantation tends to
passivate the metal surface and reduce corrosion. Thus, the wall implantation was
employed to increase the bioactivity of the metal surface and elicit the very inflammatory
responses that we were interested in investigating. The actual inflammatory response to a
stent made from the same material may therefore be less severe than what has been found
in the present study. The diameter of the wires is approximately twice that of a stent strut
of the same material, thereby introducing a greater challenge to the local arterial
environment in terms of material degradation and corrosion product clearance. The SHG,
Zn-1Al, and Zn-3Al alloy wires were extracted at four time points, including 1.5, 3, 4.5,
and 6 Months. The Zn-5Al alloy wires were extracted at 1.5, 3, 3.5, and 6 months. The
4N wires were extracted at 13 time points, including 1–10, 12, 15, and 20 months. One
of the two wires implanted into each rat was used for metallographic and corrosion rate
analysis, while the second wire was used for inflammatory characterization work (n = 28
rats). All animals survived the wire implantation surgery and made a full recovery. All
animal experiments were approved by the animal care and use committee (IACUC) of
Michigan Technological University.
At the indicated time points, wires were excised for histological evaluation and immunofluorescent labeling by collecting the entire segment of host artery that contained the
implant. To facilitate cross-sectioning, the lumen of the collected artery was filled with
PolyFreeze mounting medium (Sigma Aldrich) by syringe perfusion. Explanted arteries
were placed into plastic molds, surrounded with PolyFreeze mounting medium, and snap33

frozen in liquid nitrogen. Samples were then stored at -80°C until cryo-sectioning.
Frozen samples were cross-sectioned at a 10 μm thickness with a Thermo-Scientific HM
550 P cryostat. Tissue sections were placed on warm VWR Histobond (Radnor, PA)
slides and fixed in -20°C absolute ethanol for 60 s or in 4% formaldehyde (Sigma
Aldrich) and washed three times in PBS (Sigma Aldrich) for 5 min prior to staining.
1.2.3 SEM preparation and backscattered imaging
A JEOL JSM-6400 (Peabody, MA) scanning electron microscope equipped with a dSpec
automation system (Geller MicroÅnalytical Laboratory; Topsfield, MA) was used for
examining the explant cross sections. Imaging of the carbon-coated specimens was
conducted at 10 kV accelerating voltage at a reduced working distance using a
backscattered electron detector. The acquired backscattered electron images were
analyzed with imageJ (National Institute of Mental Health; Bethesda, Maryland) to yield
cross sectional area measurements. The bright zinc portion of the image was selected by
thresholding, in which only the area containing the brightest pixels was measured. From
these cross sectional area measurements, a metal cross sectional area reduction was
calculated for each image. The resulting measurements were averaged to yield an
estimated area reduction.
1.2.4 Hematoxylin and eosin
Slides with fixed tissue sections were rinsed in deionized water for 5 min to clear any
residual PBS. Gills-3 hematoxylin solution was pipetted onto each slide for 2-5 min, or
until over-stained (determined by visual examination). Slides were then dipped in a 900
mL bath of distilled water that had been acidified to pH = 1.8–2.0 by adding HCl. After 5
dips in the acidic bath, the samples were rinsed in distilled water for 1-5 min. Slides were
then washed twice with 95% ethanol (v/v). The slides were counterstained with Eosin Y
working solution (0.25%), which was micro-pipetted onto each slide for 45 s.
immediately after counterstaining, the slides were rinsed and dehydrated in two changes
of absolute ethanol for 5 min apiece. The slides were then cleared twice with xylene
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substitute for 5 min, and mounted under a cover slip using Eukitt mounting medium.
Samples were imaged using an Olympus BX51, DP70 bright-field microscope (Upper
Saucon Township, PA).
1.2.5 Toluidine blue
A Toluidine Blue stock solution was prepared by dissolving 1 g of toluidine blue in 70%
ethanol. A working solution was prepared by using 5mL of the stock solution and 45mL
of a 1% sodium chloride solution with the pH adjusted to 2.4 using HCl or NaOH. The
slides were then hydrated in three changes of DiH20 for 5 min each and stained in the
working solution for 5 min. The slides were then dipped 3 times in 95% ethanol and 5
times in 100% ethanol to quickly dehydrate. Slides were then dipped 20 times in each of
two clearing solutions—a 1:1 xylene substitute/acetone and a pure xylene substitute
mixture—mounted in resinous mounting medium, and imaged with an Olympus BX51,
DP70 bright-field microscope.
1.2.6 Immuno-fluorescence
Biological tissue surrounding the metal implant became impregnated with an autofluorescent corrosion product. To remove the background fluorescence due to the
corrosion product and improve the overall quality of immuno-fluorescent labeling, slides
were immersed in a 1% (v/v) acetic acid solution for 1 h to dissolve the corrosion
product. Slides were then rinsed in 4 changes of PBS for 5 min each and incubated in a
0.2% Triton X-100 solution in PBS for 30 min, followed by immersion in PBS-BSA and
a 0.2% Triton X-100 solution (blocking buffer) for 30 min. If biotinylated secondaries
were used, avidin/biotin blocking was performed for 15 min each with the endogenous
avidin/biotin blocking kit purchased from Abcam, as well as the appropriate IgG.
Primaries were then incubated overnight on the slides at 4°C in a 1:100 dilution, followed
by 3 washes in blocking buffer for 5 min each. For CD163 and CD11b antibodies, a
concentration of 1:500 was used. Secondaries were incubated on the slides at room
temperature in 1:200 concentrations for 1 h. Three washes in blocking buffer were
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performed for 5 min each and the slides were incubated with a DAPI working solution
for 1 min (1 µl/mL DAPI solution). Slides were then rinsed in 2 changes of PBS and
mounted with Perma-Fluor aqueous mounting medium and imaged with appropriate
fluorescent filters.
1.2.7 Immunofluorescent Quantification
For quantification of immunofluorescent staining, a minimum of 3 tissue sections were
taken of each sample separated by at least 100µm, and stained with the aforementioned
procedures. Sections were then imaged using the appropriate filters at 100X normal
magnification, and uploaded to MetaMorph imaging software. The entire inflammatory
exudate was included in the area selected for automatic pixel counting. Data was
recorded and graphed using Excel 2013.

36

1.3 Results
1.3.1 Backscattered imaging and cross sectional area reduction
calculations

Figure 1-1. Backscattered imaging and cross-sectional area reduction
calculation for the five evaluated zinc metal compositions, 4N wire and the four
strip materials. The backscattered images shown are for the 5 compositions at
1.5 months post-implantation, while the cross sectional area reductions shown in
the graph include samples at 1.5, 3, 4.5, and 6 months.
The SHG, Zn-1Al, Zn-3Al and Zn-5Al metal wires had the same surface finish after
electropolishing, with oxide film thickness between 100 and 200 nm. Only the 4N wire
had a native oxide film, produced during wire manufacturing, but this film had a similar
thickness as presented earlier12. Quality of the surface finish influences the early stage of
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biodegradation in the first few weeks after implantation as discussed in the cited
reference, but has no effect on corrosion of the Zn implant in later stages, as discussed in
this contribution.
Fig. 1-1 shows examples of metallographic cross sections of 1.5-month specimens.
Metallic portion of the explant is represented by the brightest area whereas oxidized
metal is in a grey color. These metallographic cross sections revealed sharply varying
corrosion behavior between the five zinc compositions that were evaluated. The 4N wire
experienced a high resistance to corrosion at this time. The SHG experienced a similar
mode of corrosion, with a significantly higher cross sectional area reduction of metallic
portion relative to the 4N material. The Al alloys experienced a similar cross sectional
area reduction as the SHG, but the surface corrosion mode shifted to intergranular attack.
1.3.2 Hematoxylin and Eosin

Fig. 1-2. Representative H&E stains of cross-sections containing the explanted
artery with the 4N wire implant. Panels A-H represent months 1, 2, 4, 5, 6, 8, 9,
20, respectively. The green asterisk in each image denotes the wire or corrosion
layer location. The scale bar at lower right is 100µm.
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The inflammatory response progression against the 4N wire implantations from 1 to 20
months is shown in Fig. 1-2. Panel A shows a small amount of cellular alignment around
the metallic implant with mononuclear infiltrates into the surrounding tissue and
negligible corrosion of the metallic implant. Panels B and C (2 and 4 months) show
progression towards a dense, non-porous corrosion product occupying the space at the
original interface between biological tissue and metallic wire, as well as an increase in
cellular density at the material interface. Panels D and E (5 and 6 months) show areas
near the interface of the implant that have become devoid of nuclei and contain irregular
nuclear features. Irregular nuclear features decrease dramatically in the peripheral tissue,
with no abnormalities in the media or intima of the artery for each time point. Panels F,
G and H (8, 9, and 20 months respectively) depict an increase in fibrotic deposition
around the implant, as well as localized chronic inflammation inside the fibrotic capsule
and around the interface Increased image size and identification of important cells/tissue
remodeling events are shown in Fig.s1-S3 and 1-S4.
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Fig. 1-3. Representative H&E stains of cross-sections containing the explanted
SHG, Zn-1Al, Zn-3Al, and Zn-5Al wire implants within the arterial wall over 1.5 
6 months, and Zn-5Al at 1.5, 3, 3.5, 6 months post implantation. The green
asterisk denotes the wire or corrosion layer position. The scale bar at lower-right
is 100µm.
The progression of the inflammatory response against SHG, Zn-1Al, and Zn-3Al,
implants at 1.5, 3, 4.5, and 6 months, as well as at 1.5, 3, and 3.5 months for Zn-8A1 is
shown in Fig. 1-3. A large corrosion layer is observed for the SHG specimens at 1.5 and
3 months, replete with macrophages and an irregular material - tissue interface. An
increase in flocculent corrosion product infiltrated with viable cells was identified on
H&E stains for SHG at 4.5 and 6 months. Tissue deposition is within the original
collagenous capsule at 6 months. An increased amount of corrosion relative to 4N and a
more intense cellular infiltration relative to SHG is observed within the corrosion layer
for Zn-1Al at 1.5 months. At 3 months, an increase in capsule density is seen for Zn-1Al
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in Fig. 1-3, as well as infiltrating cells with fragmented nuclei. For Zn-1Al at 4.5 months,
an increase in fibroblasts and cellular organization is evident, with active chronic
inflammatory cells present inside the corrosion layer. A highly organized collagenous
capsule is apparent at 6 months for Zn-1Al, with neovascularization and localized chronic
inflammation. For the Zn-3Al series of implants, a high degree of corrosion and cellular
infiltration with an ill-defined tissue material interface at 1.5 months is shown in Fig. 1-3.
At 3 months, a highly organized and cellularized collagenous capsule formed around Zn3Al, with fibroblasts present at the interface and inflammatory cells inside the interface
and corrosion layer. Some nuclear fragmentation is also visible in the cells present within
the corrosion layer. At 4.5 months for Zn-3Al, an increase in nuclear disparity was
noticed inside the corrosion layer. Collagen bundles of fibrotic character surround the
implant, with an increasing amount of acellularity relative to the 3 month specimen. At 6
months for Zn-3Al, a dense collagenous capsule with sparse amounts of cells surrounds
the implant. Macrophages still impregnate the corrosion layer and an active tissuematerial interface is still evident. The Zn-5Al 1.5 month specimen displayed the most
intense initial inflammatory reaction of all the specimens, with a high cell density at and
around the material tissue interface. At 3 months, concentric cellular alignment was
formed around the corrosion layer interface, which increased in its regularity at 3.5
months. A dense, fibrous capsule was built around the corrosion layer for the 3.5 month
time point. For more detailed descriptions, see Fig.s 1-S5-1-S8.
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1.3.3 DAPI Staining

Fig. 1-4. Representative DAPI images showing corrosion layer and tissue
interface for 4N, SHG, Zn-1Al, and Zn-3Al implants at 11.5 and 6 months. The
green dashed line identifies the interface between corrosion layer and tissue.
The yellow dashed line identifies the location of the old interface. The scale bar
at lower-right is 100µm.
Because it was sometimes challenging to clearly visualize cells present within and near
the corrosion layer in the H&E stains, DAPI staining was used to help improve the
nuclear characterization of this cell population for the different zinc materials.
Representative images for each zinc composition, excluding Zn-5Al, are shown at
approximately 1–1.5 months and 6 months (Fig. 1-4). The 4N material exhibited a slight
presence of intact mononuclear cells directly at the rigid interface at 1 month. At 6
months, a dense and uniform population of both intact and dying cells was present within
the corrosion layer. Dying cells are evident throughout this layer by the appearance of
nuclear fading, shrinkage, and fragmentation. Cells in the surrounding tissue are highly
aligned. For SHG zinc at 1.5 months, a dense and uniform population of both intact and
dying cells was present within the corrosion layer. Surrounding cells displayed some
degree of alignment as well as the general absence of inflammatory cells. At 6 months,
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the corrosion layer-tissue interface appeared to move closer to the zinc implant,
potentially indicative of a dynamic interface. The space between the new and old
interface was uniformly populated with viable cells, indicative of healthy tissue
regeneration having taken place. At 1.5 months for Zn-1Al and Zn-3Al, a high density of
mononuclear cells is present immediately adjacent to the tissue interface with the
corrosion layer, symptomatic of an intense inflammatory response in the surrounding
tissue. The coverage of cells within the corrosion layer was not uniform, with open
spaces evident at numerous locations, revealing an environment that may be toxic to
cells. These cells displayed a greater degree of intense nuclear staining relative to what
was seen surrounding the SHG material, consistent with nucleic acid condensation 13. At
6 months, the interface had advanced closer to the implant. However, the space between
the old and new interface was largely devoid of cell nuclei, symptomatic of poor tissue
regeneration. In general, the results indicate moderately healthy tissue regeneration
around the SHG implant in contrast to toxicity in combination with poor tissue
regeneration around the Zn-1Al and Zn-3Al implants due to apparent differences in the
inflammatory response. Greater detail is presented in Fig.s 1-S9 and 1-S10.
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1.3.4 Toluidine Blue

Fig. 1-5. Quantification of average number of mast cells via multiple sections
per sample.
Mast cell counting via toluidine blue staining was performed for all alloy compositions
up to 6 months as shown in Fig. 1-5. A slightly higher mast cell average is seen for the
initial months of the SHG specimen, relative to the Al alloys, with a slightly increasing
trend over a period of 1 to 6 months. The average number of mast cells counted for the
Zn-Al alloys increased more sharply over 6 months compared with the 4N and SHG
material, revealing a temporal increase of inflammatory intensity for the Zn-Al alloys.
Average mast cell counts for the SHG specimen at 6 months (±11 + 6) is slightly lower
when compared to 4N at the same time (±16 + 5). The Zn-Al alloys’ average mast cell
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count after 6 months was ±19 + 5, ±20 + 3, and ±6.526 + 7 for 2Al, 4Al, and 8Al
respectively. The Zn-Al alloy counts were all higher than for the SHG and 4N samples.

Fig. 1-6. Toluidine Blue staining of 4N (panels A, B), and SHG (panel C)
implants at 6 months. The image shown in panel A is from a region in close
proximity to the implant. The image shown in panel B is from the peripheral
tissue, approximately 1 mm from the implant surface.Yellow arrows denote mast
cells. The scale bar in the lower image is 100µm.
Toluidine Blue staining revealed the presence of active (degranulating) mast cells near
the 6 month 4N implant (Fig. 6, panel A) and in the surrounding tissue (panel B). Panel C
in Fig. 1-6 shows a positive but inactive (quiescent) mast cell staining near the 6-month
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SHG implant. All mast cells (degranulating and quiescent) were included in counting for
completeness.
1.3.5 CD68,CD11b, and CD163 fluorescence

Fig. 1-7. CD68 (green) and CD11/b (red) labeling of cross-sections containing
the explanted artery and the 4N, SHG, Zn-1Al, Zn-3Al and Zn-5Al compositions at
6 months. Cell nuclei were counterstained with DAPI (blue). High magnification
CD68 images at the tissue-material interface and in the peripheral tissue are
shown in the 2nd and 3rd rows for each specimen. The scale bar for the 100
nominal magnification shown at right (top row) is 500µm. Background autofluorescence of the elastin rich media layer is seen in the Zn-5Al specimen. The
scale bar for the 600 nominal magnification images shown at right (3rd row) is
100µm. The scale bar for the 200x nominal magnification images shown at the
right of the bottom row is 200µm.
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Fluorescent antibody labeling was performed to identify the response of CD68+ and
CD11b+ cells to the different zinc compositions (Fig. 1-7). The CD68 glycoprotein is
highly expressed in monocyte/macrophage populations (Mϕ) 14 A large population of
CD68+ cells surrounded both the 4N and Zn-3Al implants. A thick CD68+ cell layer was
established at the interface of these two materials, although the positive cell layer at the
Zn-3Al interface was more continuous and uniform relative to a more irregular 4N
interface that did not surround the entire metal specimen. The media layer in the Zn-3Al
specimen showed intense positive staining for CD68. A more detailed examination
revealed substantial damage to the ECM of the media layer in the Zn-3Al section (data
not shown). In contrast, the SHG and Zn-1Al compositions exhibited moderate CD68
labeling at the interface and sharply decreasing numbers of positive cells in peripheral
tissues, although a modest increase in positive labeling was apparent in the Zn-1Al
periphery relative to SHG.
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Fig. 1-8. Quantification of CD68 staining using average pixel counting of
multiple tissue sections per sample.
Trends of relative CD68 expression for each sample was evaluated and quantified (Fig. 18). Interestingly, the 4N CD68 expression at the 1 month time point, (2 + 1)104, ×
104 ±× 104 is substantially lower than the SHG response at 1.5 months, (10 + 3)104, ×
104 ±× 104 )with increasing vs. decreasing counts respectively.
CD11b and CD163 labeling was performed on all specimens and quantified up to 6
months (Fig.s S1 and S2). Cells that express CD11b are mostly granulocytes, such as
neutrophils. Macrophages can also express CD11b, but to a reduced extent relative to
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neutrophils. The presence and distribution of CD11b+ cells provide fundamental
information related to the stage of inflammation at a wound site. In our 6 month samples,
CD11b+ cells were present near the interface of the 4N and Zn-3Al compositions, while
the SHG and Zn-1Al compositions experienced a reduced presence of CD11b positive
cells both near and far from the interface. CD163+ cells were believed to be alternatively
activated macrophages, commonly known as M2 macrophages, and generally decrease
the inflammatory response around a wound site. They also encourage tissue repair by
releasing urea, polyamines, and ornithine15. Tissue with a more resolved state of
inflammation around an implant will contain CD163+ cells, while a chronic inflammatory
response will most likely have little to no CD163+ cells 16. In our 6 month samples,
CD163+ cells were seen very far away from the 4N implant, but not near the interface.
The SHG and Zn-1Al implants were the only implants to show CD163+ cells at the
tissue-implant interface. The Zn-3Al implant was largely void of CD163+ cells.
At 6 months, the 4N and SHG materials elicited a similar expression level (positive pixel
count, Fig. 1-S1) of CD163 labeling, (4 + 2)104 and (3 + 2)104, respectively. × 104 ±
× 104 × 104 ± 2.4 × 104 This was the case, although they demonstrated dissimilar
early time point expression values, (0.5 + 0.3)104 and (4 + 2)104, respectively. ×
103 ±× 103 × 104 ±× 104 The Zn-1Al, Zn-3Al, and Zn-5Al alloys elicited relatively
low expression levels of CD163 at 6 months, (1.6 + 0.9)104, (1.2 + 0.3)104, and (2.4 +
0.5)104 respectively. × 104 ± × 103 × 104 ± × 103 × 104 ± × 103
According to Fig. 1-S2, the Zn-1Al, Zn-3Al, and Zn-5Al alloys elicited an initially high
CD11b presence, (5 + 1)104, (4 + 1)104, (5 + 1)104, × 104 ± × 104 × 104 ± × 104 ×
104 ± × 104 when compared to the 4N and SHG materials, (3 + 1)104 and (1.8 +
0.5)104, respectively. × 104 ±× 104 × 104 ± 4.7 × 103

49

1.4 Discussion
An interesting finding in this work is that the inflammatory response evolution differed
dramatically between five zinc-dominant materials with minor additions of non-zinc
impurities or alloying elements. The compositional impurities that ranged from ~0.01
(4N) to ~0.3% (SHG) produced dramatic differences in inflammation. This was the case
despite a similar cross sectional area reduction by 6 months for all examined materials.
Surprisingly, the highest purity 4N zinc implant elicited the strongest negative immune
response. Minor impurity introductions of 0.3 wt.% (SHG) produced the best performing
zinc implant of the five, with a highly biocompatible immune response. The results
demonstrate that the immune response against zinc implants was not related to zinc per
se, but is rather shaped by the material’s intrinsic corrosion behavior. Because zinc 4N
corrosion rate at early times was substantially lower than that of SHG zinc, we speculate
that the initial corrosion rate may be a critical regulator of inflammation.
An analysis of the histological and metallographic data provides insight into the potential
mechanism by which the corrosion rate may regulate the inflammatory response. For the
4N composition, a necrotic response at 5, 6, and 8 months (Fig. 1-2, panels DF
respectively) is highly indicative of inflammation-induced matrix remodeling around the
implant. The necrosis is believed to have occurred due to the generation of a mature
fibrotic capsule between 4 and 6 months, coupled with what appear to be intense,
localized corrosion events that damage the fibrotic capsule. We have reported that the
stable ZnO layer present around the 4N implant increases into a bulk corrosion product at
4.5 and 6 months 9. The temporal trend of necrosis appearing by 5 months and a bulk
ZnO product appearing by 4.5 months is associated with our recent report that the 4N
zinc corrosion rate accelerates between 4.5–6 months 9. Recent electrochemical and
thermodynamic characterization of zinc corrosion as a function of pH 17 has identified
ionic zinc as the most stable species of zinc at low pH conditions (pH ~ 1- 4) Zn2+17,
while ZnO is the most thermodynamically stable phase of zinc at physiological pH. The
presence of necrotic tissue at the 4N interface (Fig. 1-2) at the time points where we
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found an increased corrosion rate [8]. Such an environment could have materialized if
frustrated phagocytosis by foreign body giant cells (FBGCs) and resident Mϕs at the 4N
implant lowered the interfacial pH to acidic conditions. The resulting ionic Zn2+release
could induce massive cell death near the implant surface, due to a low reported cell
tolerance to ionic zinc 8a, 8d, and stimulate fibrotic tissue deposition. This putative
mechanism may explain the widespread cell death seen at 5, 6 and 8 months and the
ensuing fibrotic capsule growth near the surface of the 4N material, at which time points
we have also found a high CD68 and CD11b signal. Similar reasoning could also explain
the lack of cell death in the SHG material. In this case, downward temporal trending of
CD68+ Mϕ (Fig. 1-8) around the SHG implant may reflect a near neutral pH interfacial
environment and effective Mϕ clearance of porous ZnO and ZnOH corrosion products.
It is well known that foreign particle size and scaffold porosity affect Mϕ signaling,
phagocytosis, and fusion 18. We speculate that the initial low corrosion rate of the 4N
material may have elicited macrophage fusion (observed, but not shown) by presenting a
rigid interface and eventually large corrosion particles or a low porosity scaffold to the
surrounding tissue. Mϕ fusion / foreign body giant cells can cause tissue damage by
releasing powerful enzymes and reactive oxygen species in an effort to degrade the
material into smaller, digestible particles 19. Interestingly, the 4N corroding implant
elicited the degranulation of mast cells (Fig.s 1-5 and 1-6), The findings of inflammatory
events at 6 months for the 4N material that are normally associated with acute
inflammation (Fig. 1-5) are consistent with the concept of an increased Mϕ activity that
accelerates corrosion and increases toxicity to cells near the implant surface.
In contrast, the SHG and Zn-Al metals all appear to degrade earlier than the 4N material
and produce a relatively thick and porous corrosion layer (Fig. 1-3). This also correlates
well with temporal CD68 expression, as presented in Fig. 1-8. The porosity is apparent
due to the increased consistency of cellular infiltration within the corrosion layer for SHG
and the Zn-Al alloys. The ability of inflammatory cells to penetrate the corrosion layer at
early times may explain the reduced thickness of the fibrous capsule in SHG relative to
4N. Interestingly, the 4N material was the only implant to elicit an acellular fibrotic
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encapsulation response, despite the similar material compositions and preponderance of
zinc amongst the SHG and Zn-Al wire implants.
Surprisingly, the SHG material was the only material to elicit a relatively moderate
amount of CD163 expression through the entire 6-month implantation time (Fig. 1-S1).
The Al alloys all had consistently low expression of CD163 over the time course, with a
large increase of expression over 6 months for the 4N material. The consistent presence
of CD163+ cells around the SHG material could explain its positive tissue remodeling
and integration, while the 4N response could be explained as an effort to reconFig. the
arterial damage due to the necrotic response shown in Fig. 1-2.
Although cells had penetrated the corrosion layer at early time points in the SHG and ZnAl materials, a decrease in cell viability can be seen from SHG, to Zn-1Al, and then Zn3Al, respectively, with the SHG corrosion layer exhibiting the fewest irregular cells. The
graded differences in cell viability within the corrosion layer of the Zn-Al alloys may
explain the increasing capsule thickness from SHG and Zn-1Al to Zn-3Al, as well as the
lack of a dense collagenous capsule for the SHG material, as seen in Fig. 1-3. Fig. 1-8
clearly shows high initial CD68 presence for the Al additions, which could be indicative
of a highly aggressive macrophage attack in the early weeks of implantation. The graded
difference in cell viability was associated with the degree of CD68 labeling, suggesting
that Mϕ activity may have contributed to the reduced cell viability within the corrosion
layer. Although the presence of aluminum appeared to have elicited a greater
inflammatory response, the Al3+ is not believed to be harmful, because there was no
indication of toxicity to cells away from the regions of tissue where the macrophages had
clustered. Potentially, the aluminum addition may have produced corrosion products
(possibly Al2O3) that are too small or chemically stable for efficient phagocytosis,
resulting in an increased residence time and build-up of Mϕs in and around the corrosion
layer. Another explanation is that the intergranular mode of corrosion may elicit a more
robust inflammatory response relative to the surface corrosion experienced by the SHG
material. For instance, oxygen gradients established by its transport into the metal
interior through grain boundaries may stimulate secretion of harmful reactive oxygen
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species by Mϕs. Lastly, Zn-Al corrosion may increase the pH near the implant 20,
resulting in cell toxicity due to hydroxide ion transport from the material to the biological
tissue.

1.5 Conclusions
Zinc implants produced dramatic differences in inflammation in rat arteries. The
differences in biocompatibility of zinc materials are attributed in this study to their
compositional dissimilarities that cause variations in implant corrosion activities and zinc
ion fluxes. We conclude that the corrosion behavior (surface vs. intergranular), corrosion
rate, corrosion product porosity, and the presence of a dynamic tissue-material interface
regulate the inflammatory progression and remodeling of surrounding and penetrating
tissue. Mϕs and their monocyte precursor are known to orchestrate the fibrotic response
in an up/down regulatory manner 21, making them the key cells that mediate
inflammation and implant degradation. The ability of Mϕs to penetrate and remain viable
within the corrosion layer at early times may be of fundamental importance for eliciting
long-term biocompatible inflammatory responses around corrodible metals. Future work
will aim to further clarify the mechanisms by which zinc metallic implants regulate Mϕ
activity and viability with the aim to control inflammatory responses around vascular
implants made from zinc base materials and predict long-term biocompatibility from
early stage corrosion behavior.
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2 Development of novel in vivo methodology to screen
degradable materials for biodegradable stent
development 3 4
2.1 Introduction
Zinc alloy development and materials characterization for vascular stent application has
been facilitated by a plethora of standardized and inexpensive methods. These methods
have been employed over the past several years to generate a number of candidate zinc
based alloys for vascular stents [1-3]. In contrast, the biocompatibility evaluation of zinc
based degradable biomaterials for vascular applications has been challenged by a lack of
standardized procedures at early developmental stages. While materials that have been
selected for stent prototyping are commonly evaluated in a large animal stent
implantation model using procedures designed for human subjects, such an approach is
prohibitive for evaluating early stage materials due to its high cost and requirements of
medical-grade facilities and medical expertise. With the steady accumulation of new zinc
based materials [2], a standard and inexpensive approach for the biocompatibility testing
of degradable metals for vascular applications is urgently needed.
Historically, the degradable metals community has relied upon in vitro evaluation of
candidate materials to assess biocompatibility. In this fashion, cell culture approaches
dominate the preliminary biological testing, with investigators focusing their attention on
either cytotoxic or mechanistic investigations. Cultured cells are exposed to Zn2+ ions [46] or corrosion extracts collected and concentrated from candidate materials that were
corroded in one of a number of different corrosion solutions [7-10]. These have become
standard approaches that can provide fundamental insight into the interactions between
corrosion products and various cell types.
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While directly investigating cell responses to corrosion products provides a fundamental
understanding of the biologic response, results are not directly applicable to the
compatibility of the material in the application environment. An artery is a complex
tissue with three main resident cell types (media - vascular smooth muscle cells, intima endothelial cells, and adventitia - fibroblasts). While the cytotoxicity and sub-cellular
response of any of these three cell types is important for determining the overall
compatibility of the tissue to degrading zinc materials, molecular cross talk, differences
in proximity between the three arterial compartments to the implant, and interaction of
blood borne cells play an important role in macro-level vascular responses, which cannot
be replicated in vitro [11]. For instance, activation of an organism’s innate immune
system by biomaterial implantation and tissue injury will impact the overall reaction
against the material, critically affecting device performance [12]. Furthermore, the
corrosion of zinc based materials varies widely between corrosion solutions and
physiological conditions. A distinction must be drawn between cell toxicity (obtainable
from direct exposure of cultured cells to Zn2+ or corrosion products) and application
specific biocompatibility (requiring in vivo assessment of the material in the appropriate
physiological environment).
Stents implanted into the arterial environment are expected to restore and maintain
continued function of the artery. Harmful events, including smooth muscle cell
neointimal proliferation, thrombogenesis, negative arterial remolding, and destructive
inflammation contribute to the narrowing of the lumen and restenosis of the stented
segment. While measurements of cytotoxicity can contribute to predicting negative stent
outcomes, it cannot replace direct application-specific testing. For instance, magnesium
and iron biometals perform superbly when measured for cytotoxicity, but struggle in the
application environment due to drawbacks in their corrosion rates that eventually lead to
device failure [13, 14].
In 2012, our group introduced a metal wire implantation model as a cost effective and
simplified approach for the biocompatibility evaluation of degradable materials in the
vascular environment [15]. Any material that can be drawn into a 0.20-0.25 mm nominal
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diameter wire can be evaluated in this model to investigate material biocompatibility.
Implanting a wire into the lumen of the abdominal rat aorta rather than a stent into a pig
is promising from a device testing standpoint: the wire affords a simpler geometry
without balloon injury, and is less expensive in terms of animal costs, materials
preparation, and corrosion analysis.
In this contribution, we aim to describe a cost effective histomorphometric standard for a
pipeline-based evaluation of candidate degradable materials using the murine based wire
implant model. Herein, wires made from two zinc alloys and pure zinc were implanted
into the abdominal aorta of Sprague Dawley rats and collected at 6 and 11 months.
Neointima tissue surrounding the wire was measured for area, thickness, and protrusion
into the arterial lumen, critical metrics for quantifying vascular application based
biocompatibility.

2.2 Experimental
2.2.1 Materials
Staining reagents include powdered iron hematoxylin (H3136), sodium sulfate
pentahydrate (Na2SO4•5H2O) (753599) anhydrous iron (III) chloride (FeCl3 )powder
99.99% (157740), phosphate buffered saline pH 7.4 (PBS, P4417) , Lugol’s iodine
solution(624-71), xylene substitute (78475), Van Gieson solution (HT254), and Eukitt
quick hardening mounting medium (03989); all were obtained from Sigma
Aldrich(Burlington, MA). 200 proof Ethyl alcohol (absolute ethanol) was obtained from
Pharmco-Aaper. Neutral buffered formalin 10% ( HT501128 ) was also obtained from
Sigma Aldrich.
2.2.2

Surgical Implantation

For the present study, a complete histological characterization of metallic wires
implanted into the rat abdominal aorta was explored. Pure zinc (Zn) (number of samples)
=10, zinc-4 wt. % lithium (Zn-4Li) (number of samples) =10, and micro-alloyed zinc59

magnesium (number of samples) =12 (either Zn-0.01 wt. % Mg or Zn-0.1 wt. % Mg,
hereafter referred to as Zn-XMg) wires were implanted and collected at 6 and 11 months.
Two sample sites were evaluated per wire (near both puncture sites for each wire)
resulting in n=64. Greater details of the Zn, Zn-4Li, and Zn-XMg wires used in the
present study can be found in references [16, 17].

Fig.2-1 Panels 1-9 show the surgical depiction of wire implantation. Yellow “V”
and blue “A” denotes the inferior vena cava and descending abdominal aorta
respectively. Purple “W” highlights a wire for insertion. Panel A shows the
Sprague Dawley rat in the supine position with the abdominal area shaved and

60

cleaned before procedure. B shows the abdominal muscle with multiple sutures.
C shows the skin clamped with stainless steel staples.
All animal experiments were approved by the Michigan Technological University
IUCAC board. Rats were anesthetized in the supine position using an O2 rich isoflurane
vaporized gas mixture. The abdomen was shaved and cleaned using antiseptic wipes
(Fig.2-1a). For the initial incision, the skin was cut with dissecting scissors through the
midline starting approximately 3 cm above the pelvic region and terminating after
approximately 5-8 cm. The abdominal muscle was cut in a similar fashion (step 1 of
Fig.1). With the viscera exposed, intestines were carefully pushed aside in order to
visualize the caudal descending abdominal aorta and vena cava (step 2). Connective
tissue surrounding the vessel was carefully pushed aside with Q-tips to completely
expose the vessel. In order to continue with the implantation, blood flow must be briefly
interrupted, which is accomplished by placing vascular clamps inferior to the renal
arteries and superior to the aortic bifurcation. First, the aorta and vena cava must be
carefully separated by using blunted forceps. This is accomplished by carefully poking
through and then enlarging an opening between the vessels to fit the clamp. After
separation, the proximal clamp is placed first, then the distal clamp applied (steps 3-6). A
wire sharpened by angular cuts (using very sharp scissors) is poked into the artery at a
location superior to the distal clamp (steps 7 & 8). After insertion, the wire is advanced
within the artery and then punctured out of the artery, producing a second puncture site.
The wire is left in place with ~2 - 3mm of wire exteriorized from the artery at both ends.
Zinc wires do not need to be secured in place, because corrosion activity embeds the wire
within the tissue. If biostable wires are implanted (as controls, for example), the wires
must be secured in place to prevent shifting. The vascular clamps are removed (the distal
clamp is removed first). The abdominal muscle is sutured together, and the skin clamped
(panels b & c). The rat is allowed to recover under observation, following a subcutaneous
injection of butorphanol for pain management. Proper mobility of the lower limbs is used
as an indicator of continued abdominal aorta function. All animals survived the
procedure.
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2.2.3 Implant removal and gross examination
Rats are anesthetized using a vaporized isoflurane and O2 rich mixture. After the subject
is deeply anesthetized, the abdominal aorta is isolated from the surrounding tissue. The
diaphragm is punctured and the heart is removed from the thoracic cavity to ensure death.
The aorta containing the wire is then collected and examined grossly for any obvious
abnormalities. The aorta is then placed in a small cryo-mold, surrounded by optimum
cryo-temperature cutting medium, snap frozen in liquid nitrogen, and stored at -80°C
until cryo-sectioning.
2.2.4 Tissue preparation and histological evaluation
Specimens that are snap-frozen can be stored at -80°C for up to one year while
maintaining tissue integrity. To prepare for histological evaluation, the implant
containing aorta is oriented to ensure a cross-sectional profile of the wire/artery. The
artery is then freeze-mounted on a specimen chuck, and placed onto the head of a cryomicrotome for cryo-sectioning. In our experience, a blade angle of 12 degrees and a
chamber temperature of -24°C to -26°C is optimal for these samples. A section thickness
of 5-10 µm can be reliably produced, but for the present study all sections were taken at a
section thickness ≈8 μm. We initially section rapidly through the exteriorized portion of
the wire while visualizing the wire in the sample (with a hand-held magnifying lens) as it
moves progressively closer to the artery. Once the wire in the specimen can be seen
within the wall of the artery, the sample is more carefully sectioned until the wire appears
to pass the internal elastic lamina. The wire position in the sample can be verified by
inspecting cross sections on an inverted microscope equipped with polarized light filters.
When the wire has crossed the internal elastic lamina, sections are collected on slides for
later staining, with multiple sections per sample collected.
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Fig.2-2 VVG staining, Panels 1-3 highlight the sectioning progression of the wire
position in relation to the artery. Red “w” shows the Zn wire and yellow arrows
are positioned at the first elastic fiber. Cartoon depiction displays four most
common neointima types, with the explained morphometric measurement
locations in relation to the neointimal formation.

This process is seen in Fig.2-2, with clear progression of the wire into the luminal space
of the artery. To ensure a representative characterization is performed, cross sections are
collected over a distance of 100-500 m into the specimen. As the sample is
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progressively cross-sectioned, the wire may eventually appear to “free float” in the
arterial lumen. Cross sections where the wire is not in contact with the artery are not used
for histological analysis. Cross sections near the second puncture site can be collected
either by flipping the specimen over on the chuck and repeating the procedure described
above, or by continuing to section through the sample, although this is more labor
intensive. By this method, cross sections near both puncture sites from the implant can be
obtained.
Histological Staining and Morphometric Analysis
Slides with frozen sections were fixed for 10 min at room temperature using a bufferedformalin solution. After fixation, the slides were washed 3 times for 5 min each in
phosphate buffered saline. A hematoxylin and eosin stain (H&E) was carried out as a
general stain in order to visualize tissue constituents and qualitatively assess vessel
morphology (see the following reference for procedure details [18]). A Veorohoff Van
Geison elastic tissue stain (VVG) was carried out to identify the elastic laminae within
the artery. This provides anatomical landmarks for the histomorphometric analysis.
For Veorohoff Van Geison staining, slides with tissue sections were fixed in 10% neutral
buffered formalin for 10 minutes. Slides were then washed in three changes of PBS for 5
min each and overstained in Verhoeff’s elastic stain for 10 min (30 mL of absolute
ethanol and hematoxylin solution 5% m/v, 12 mL of deionized water and FeCl3 solution
10% m/v, and 12 mL of Lugol’s solution). The slides were then differentiated using an
inverted optical microscope with a FeCl3 solution diluted to 2% m/v until elastic fibers in
the media layer of the arterial cross- section was well defined, and non-elastic tissue
became unstained. The slides were then rinsed in deionized water for 5 min. The slides
were placed in a deionized water and Na2SO4•5H2O solution, 5% m/v for 1 minute and
then rinsed in running tap water for 5 min in order to “blue” the hematoxylin. The slides
were counter stained in Van Gieson solution for 3 m and microscopically differentiated
in a 95% v/v ethanol solution until there was a clear distinction between the pink Van
Gieson stained adventitia and the brown stained media. The slides were dehydrated in
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two changes of absolute ethanol for five min each. The slides were then optically cleared
with two changes of xylene substitute for 5 min each and mounted under a coverslip
using Eukitt quick hardening mounting medium. The samples were imaged using an
Olympus BX51, DP70 bright-field microscope (Upper Saucon Township, PA).
Neointimal area (NA), wire-to-lumen thickness (WLT), and base neointimal length
(BNL) were measured using METAMORPH software. Cross-sections stained with VVG
and imaged at 100X normal magnification were used for the measurements. The
neointima was considered as tissue surrounding the implant on the luminal side of the
first elastic fiber, which was highlighted by VVG staining, with the wire cross sectional
area excluded. All neo-tissue growth contacting the implant was included in the
measurement, as well as all significant intimal activation in nonadjacent regions. WLT
was measured near the apex of the neointima, at the point where the tissue protruded
furthest into the lumen. For BNL, the first elastic fiber was traced (below the wire
implant) until negligible neointimal activation was observed (Fig.2-2). Multiple sections
of each sample were evaluated to ensure a representative depiction of each sample
(minimum of 5 sections). Only sections that satisfied quality concerns (section not torn
considerably, neointima still intact, low amount of section folding) were measured.
Zn Accumulation in Organs
To provide insight into whether zinc is cleared or retained with the body during implant
degradation, the organs that play a major role in the distribution, filtering and regulation
of the fluid compartment and constituents were analyzed for zinc concentration. Wires
were implanted within the abdominal aorta for 6 months, whereupon the heart, blood
plasma, liver and kidney were collected. Using a fluorometric zinc quantification assay
(ab176725) and a Bradford assay (ab102535), all purchased form Abcam (Cambridge,
MA), zinc levels were determined relative to control tissue (collected from non-implant
rats), and reported in g/mL.
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2.2.5 Statistical Analysis
Histomorphometric data was uploaded into MATLAB R2018a. A Wilcoxon ranksum
test was performed on all test groups within each respective time point (6 or 11 month
implantation) relative to the reference Zn implant. A p value <0.05 was considered
significant. Data plotted in boxplot graphs show the upper and lower quartiles (25%75%) within the boxed region, 0% and 100% quantiles within the whiskers, with red ‘+’
as computed outliers. For tissue derived Zn2+ organ concentration, a two-tailed student’s
t-test with assumed equal variances was used to determine significance between control
and test groups. Bar graphs denote sample mean, with error bars in standard deviation. A
p value <0.05 was considered significant.

2.3 Results and discussion
The development of zinc-based metals is advancing in academic institutions although it
has not yet reached the clinical stage. The potential for targeting multiple vascular
applications as degradable vascular implant materials has sparked intense interest
amongst metallurgists and corrosion scientists with expertise in materials development.
To the authors’ knowledge, most of the in vivo work published to evaluate zinc based
materials in the vascular environment has emerged from our group, with a single
contribution based on pure Zn stents deployed in the rabbit abdominal aorta by Yang et
al, [19]. In order to develop a coherent framework for the early in vivo testing of zinc
implant materials, we have provided extensive details of our small animal model,
including surgical, tissue sectioning, and histological staining procedures. We have also
developed metrics to quantitatively characterize the long-term histological progression of
the neointima that forms around zinc based wire implants. The approach used here could
become a standard in the field, which would allow direct comparison between
biodegradable materials developed by different laboratories throughout the world. The
metrics we have developed for the wire model have been adapted from metrics that are
used to characterize the neointima that forms around vascular stents. Therefore, these
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metrics may help predict performance of the same material when deployed as a stent in a
large animal model.
General histological presentation
The evaluation of neointimal characteristics provides critical insight into the biological
performance of intraluminal implants. Stent performance is routinely evaluated by
specific morphometric characteristics including lumen area, neointimal thickness,
neointima area, and internal elastic lamina area [20-22]. The wire implantation model
simulates a single stent strut placed within the lumen of an artery, without concomitant
radial luminal injury or mechanical excitation of the implant. As it is known that radial
force exerted during balloon catheter deployment provokes inflammation and smooth
muscle cell proliferation[23], the present model allows us to investigate the host response
to the experimental material without confounding effects related to deployment. Classical
stent metrics such as lumen area and external elastic lamina area (used to determine
positive and negative remodeling) are not useful when using the wire model, due to the
wire not engaging the entire artery circumferentially. The characteristics of the developed
neointima surrounding the wire implant provides the most useful information relevant to
implant performance. Fig.2-2 (lower box) summarizes the various neointima types that
dominate most observations in our wire model. Type 1A neointima formations are
considered ideal, with a low profile and a stable, mature tissue response to the implanted
wire. Type 1B formations are common at longer time points (11 months), and in our
experience are believed to be the natural temporal progression of Type 1A formations.
Type II formations reflect the negative responses seen in this model. The characteristics
of Type 2A are assumed to be analogous to negative arterial remodeling of a stented
artery, which contributes to luminal area reduction and reduced vascularization. We have
seen this response in our previous investigation of Fe wires and in a more dramatic
fashion with PLLA coated Zn wires [15, 24]. The failure mode of this formation consists
of vascular smooth muscle cell (VSMC) neointima hyperplasia, which we confirmed by
alpha actin positive staining (data not published). Type 2B presents as a thin neointima
with voluminous corrosion product and a cell rich middle layer. The consistent thin tissue
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surrounding the implant could result in rupture, which is not ideal for stenting
applications.

Fig.2-3 H&E staining, 4 representative sample cross-sections of each implant at
6 and 11 month residence. Images are taken at 100X normal magnification and
scale bar is approximately 1mm.
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In order to properly characterize neointima formations, thin tissue sections must be
prepared and stained for each sample. Hematoxylin and eosin is the most common,
general histological stain and we have routinely used this stain to evaluate materials
implanted in the rat model [15-18, 24, 25]. Fig.3 shows multiple representative cross
sections of 6 and 11 month samples that have been stained with H&E in order to visualize
neointimal formations. Inflammation and macro-level cellular responses can be readily
identified at high magnification in these H&E images, which we have demonstrated
elsewhere [18, 25]. Considering the presence and distribution of cellular type and
inflammatory responses directly influence neointimal formations and contribute to the
compatibility of intraluminal implants [23], a reliable and straightforward workflow of
neointimal morphometric characteristics can be used to describe the overall cellular
response to the material. To make measurements that describe the neointimal character, a
VVG stain is more appropriate because this stain can be used to distinguish the different
layers of arterial tissue.

Fig.2-4 VVG staining, 1 representative sample at each time point for the alloys
investigated. “W” denotes wire position. Scale bar is approximately 1mm
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The elastic fibers (black) provide anatomical landmarks for NA and BNL quantifications,
which are also identifiable but far less prominent on an H&E stain. Fig.4 shows a
representative VVG stain of each implanted alloy at 6 and 11 month time points. A
general progression of Type 1A to 1B formation can be seen for the Zn wire. The Zn-4Li
specimens generally display increased intimal activation away from the implant, with a
reduction of elastic fibers near the implant. For Zn-XMg wires, large Type 2A and 2B
formations are often seen at both time points, with a high variation in neointimal
responses.

Fig.2-5 VVG staining of samples at indicated lumen obstruction index (LOI).
Failure threshold is shown at 30%. Tabulated morphometrics for the three alloy
systems investigate at 6 and 11 months.
Identification of optimal performance
In order to quantify the direct success or failure of candidate materials, a lumen
obstruction index was developed to describe negative histomorphometric appearances.
To obtain the lumen obstruction index of a sample:
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WLT

LOI= [BNL‐Φ] ×100%

(1)

where WLT is the wire to lumen thickness, BNL is the base neointimal length, and Φ is
the nominal wire diameter, here as 250 μm. Presumably, a native artery that lacks a wire
implant and has normal intima anatomy would have an LOI of 0%. An index of 30% was
set as the cutoff for degradable material success. This cutoff was based on the largest
index measured for a pure Zn wire implant, out of 60 observations. Visual depiction of
the failure index is presented in Fig.2-5, with the cutoff (dashed red line) identifying the
failed pure Zn neointima. Out of all observations at both time points, one Zn implant at 6
months and three Zn-XMg implants at 6 months exceeded the failure threshold. These
implants were not included in the subsequent statistical analyses.
Fig.6 shows measurements from histological sections for samples at the two long-term
evaluation time-points. At 6 months, no statistical differences exist between the Zn
reference and Zn-4Li / Zn-XMg alloys for any metric. Additionally, the average WLT for
Zn and the Zn-4Li/Zn-XMg alloys appears modest (67 ± 36 µm vs 47 ± 28 µm / 42± 14
µm respectively). All three failed Zn-XMg implants and the one failed Zn implant
occurred at 6 months, indicating this time point could be useful as the minimum to
observe failure. For the 11-month implants, all metrics for the alloys were significantly
increased relative to the pure Zn reference material. WLT for the Zn-4Li and Zn-XMg
systems (90 ± 59 µm and 77 ± 38 µm) is significantly higher than for Zn, 60 ± 69 µm at
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Fig.2-6 Boxplot representation of metrics at each time point, for each alloy
system. The upper and lower quartiles (25%-75%) are within the boxed region,
0% and 100% quantiles within the whiskers, with red ‘+’ as computed outliers.
Significance was determined by a Wilcoxon rank sum test, with p values in
respect to the reference zinc sample at each time point. “*” p<0.05, “**”
p<0.005, “***” p<0.0005.
11 months. Zn WLT appears unchanged from 6 to 11 months, while this metric appears
to have increased markedly for Zn-4Li and Zn-XMg implants.
Neointima thickness is commonly used to gauge arterial responses to stenting due to its
correlation with stent failure and luminal area reduction [26-28]. In the present study,
neointima thickness progression measured by WLT appears to be a reliable metric in
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determining compatibility. Furthermore, when divided by the length of neointimal
activation (BNL) it can serve as an indicator of negative remodeling (closer to 100%
indicates excessive protrusion within the lumen). The area of the neointima (NA) is
important, but does not provide enough information to adequately describe performance
of the material. For instance, two implants can have similar NA measurements but
dramatically different failure indices. Therefore, NA is not recommended as a standalone metric for compatibility, but as a complementary evaluation.
Although a failure threshold of 30% is recommended, neointimal formation values
greater than 20% should denote poor performance. Although none of the Zn-4Li implants
met the failure threshold, multiple instances of increased WLT with failure indexes close
to 20% (data not shown) suggest a reduction in compatibility for the Zn-4Li wires
relative to pure Zn.
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Fig.2-7 Zn Organ quantification by a flourometric assay. Bar graphs represent
mean and error bars are ± standard deviation of the samples. Minimum n=3 for
each condition, significance was determined by a two tailed students t test, “NS”
not significant
An organ analysis can also be performed on each animal, as shown in Fig.2-7. This
analysis demonstrated a slight increase in plasma bearing Zn, with no accumulation of
zinc in the heart, liver, or kidney. This finding suggests that zinc removed from the
implant is safely transported and excreted from the body.

Fig.2-8 Workflow of wire model showing alloy development and biocompatibility
testing
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The wide variety of Zn-alloy systems that can serve in degradable cardiovascular stent
applications has opened exciting possibilities for a number of candidate materials. The
most appropriate approach for assessing the biocompatibility of degradable metals
remains an important and open question for materials selection. Here, we present a robust
workflow, summarized in Fig.2-8, for the testing of degradable metal candidates.
Candidate materials are designed, extruded into rods, drawn to ϕ=0.25 mm wire, and
characterized for mechanical and microstructure properties. The wires are then implanted
into the lumen of Sprague Dawley rats and allowed to maintain residence for up to
approximately 1 – 2 years. Implants are then collected and histologically processed for
biocompatibility assessment. Based upon quantification of metrics as outlined in the
present contribution, informed decisions related to alloy design are iterated into the
workflow, or selected materials can progress to stent testing in large animals. A summary
of these proposed metric values are given below.

Table 2-1: Summary of the proposed biocompatibility values given by the wire model
Metrics

Biocompatibility standards ( 6-months)

Lumen obstruction index

≤ 30%

(LOI)
Wire to lumen thickness

≈ 70 μm

(WLT)
Neointima Type

Type 1 (A or B)

Based upon the metrics developed here, pure Zn elicited the best biocompatibility of the
three evaluated materials. An excellent biocompatibility response for pure Zn in the wire
model is consistent with what was reported for pure zinc stents implanted within the
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rabbit abdominal aorta [19]. Therefore, the metrics we have developed based on implant
materials in wire geometry may be predictive for the biocompatibility of stents deployed
in large animals. Zn-4Li exhibited a reduction in biocompatibility at 11 months relative
to pure Zn due to the progression of its WLT. Although no Zn-4Li wires incurred a LOI >
30%, numerous implants incurred elevated LOI measurements above 10%. The present
finding of a non-obstructive neointima is consistent with previous preliminary
observations of Zn-4Li wires made by our group [17].
Zn-XMg performed the worst of the three implanted materials, based on three failures at
6 months, as determined by LOI, and a significant increase of WLT at 11 months relative
to pure Zn. This reduction in compatibility was also reported previously, and may be due
to an increase of inflammation in Zn-XMg implants [16]. Due to the well-known
compatibility of Mg, the authors speculate that the performance reduction was unrelated
to the inclusion of Mg directly. Rather, the worsened response may have been caused by
changes in corrosion behavior or the generation of intermetallics of reduced
biocompatibility. These factors gave rise to Type 2A and 2B neointima formations, even
within the same sample (not shown), confirming our earlier work highlighting the
importance of corrosion behavior for regulating biological responses[18].

2.4 Conclusions

We conclude that:
Biocompatibility can be reliably determined using the rodent wire implant model
Six months is the minimum viable time point to confidently determine biocompatibility
Quantifications of neointima characteristics, including wire to lumen thickness and base
neointima length, can describe the overall performance of degradable implants.
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A reduction in biocompatibility relative to pure zinc is seen for the Li and Mg alloy
systems.
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3 Contributions of the surface characteristics of
degradable zinc implants to the neointimal response
and subsequent biocompatibility5 6
3.1 Introduction
Zinc (Zn)-based metals are emerging materials for biodegradable cardiovascular devices14

. Although many questions remain, a number of recent preclinical studies have reported

an encouraging efficacy for pure zinc and Zn alloy based stents5-7. Additionally, Zn-based
metallic implants are steadily closing in on the mechanical benchmarks required for
stenting human arteries7-9. However, in addition to mechanical strength and ductility,
degradable Zn-based stents may require an engineered surface oxide film to initiate a
relatively uniform corrosion and biocompatible host response in early stages of implanttissue interactions10-12. While there has been considerable progress in the development of
novel Zn-based degradable alloys with improved mechanical and structural properties,
the development of surface films has consistently lagged behind10, 13. This is probably
due to widely accepted standards for permanent stents related to smooth and
electropolished surfaces, which may not apply directly to degradable metals.
A key feature of degradable Zn is an in vivo corrosion rate that is sufficient for device
dissolution within 1-2 years11. Interaction with the host occurs at the Zn implant-tissue
interface throughout the service lifetime, although the Zn-based substrate interface
changes over time14. Continuous corrosion at the implant interface and the production of
various biodegradation products elicit a host response that is sustained until the implant is
fully degraded. It is well known that a change in the passivity or susceptibility to
corrosion is determined largely by the surface film characteristics15-17. However, the ideal
surface properties for degradable Zn materials remain an open question. Critically, a

5
6
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surface that inadvertently provokes a rapid or non-uniform corrosion of the underlying
degradable Zn substrate could result in localized metal dissolution and changes in pH.
These processes, if not controlled, may be harmful to surrounding cells, initiate
inflammation and/or neointimal growth, and increase susceptibility of implant to stress
corrosion cracking. In contrast, an improved biological response and mechanical
performance could be imparted from engineered Zn surfaces that increase corrosion
resistance and corrosion uniformity.
Conventional biostable stents are commonly surface treated by electropolishing (EP) to
create a smooth surface finish with a thin, stable oxide layer that protects the underlying
metal from corrosive attack18. Since degradable metals are designed to corrode, a thin EP
surface layer may be highly sensitive to local variations in cells and tissue composition.
In contrast to EP, the anodization (AD) of metal surfaces may increase the stability of the
surface layer and therefore reduce its sensitivity to non-uniform penetration from local
variations in the biological milieu19, 20. Both EP and AD processes are widely used in the
biomedical industry as surface finishing treatments10, 21. During EP, the surface material
is removed by anodic dissolution leaving a smoother surface with reduced roughness and
improved cleanability22. AD consists of an electrolytic passivation, which is used to
increase the thickness of the natural oxide layer of the implant. Both EP and AD
procedures have been reported to dramatically improve the biological performance of
permanent23-26 and degradable implants.
The EP and AD protocols are well developed for inert implant materials such as stainless
steel, titanium alloys and cobalt alloys. However, they are in their infancy for Zn-based
implant materials. Here, we describe methods to exert control over the formation and
uniformity of surface oxide films on Zn material surfaces using electropolishing and
anodization processes. Zinc materials with engineered surfaces were characterized by
electrochemical methods. They were then implanted into Sprague Dawley rats for 2-8
weeks in an effort to correlate neointimal responses to surface oxide film characteristics.
We found that anodization of Zn implants, although not commonly applied to vascular
stents, could benefit the biocompatibility of Zn-based stents if engineered appropriately.
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3.2 Experimental
3.2.1

Surface preparation

High purity (99.99%) Zn wires (d = 0.25 mm) and discs (d = 8mm), ethanol (C2H5OH),
butanol (C4H9OH), aluminum chloride hexahydrate (AlCl36H2O), zinc chloride (ZnCl2),
oxalic acid ((COOH)2), and industrial detergent (Citranox ®) were purchased from Sigma
Aldrich (St. Louis, MO, USA). The EP process was optimized bearing in mind criteria
that provide reduced surface roughness and dimensional precision aimed to minimize
thickness loss, which is of paramount importance for thin wires and stents. The
electrolyte was designed based on the indications of ASTM E1558-09 standard27.
Regarding anodization, the process parameters were selected to allow maximum surface
coverage with minimum coating thickness. The study consisted of Zn wires and discs
treated under a combination of different voltages, mixing speed, electrolyte concentration
and treatment duration. The EP and AD sample surface finish was assessed by
microscopic observations. Subsequently, the samples exhibiting desired surface
properties were selected for in vitro and in vivo degradation study. Zn samples were
cleaned with a detergent, then subjected to an ultrasonic cleaning process in pure acetone,
followed by rinsing with deionized water. After that, the specimens were electropolished
with an electrolytic solution comprised of C2H5OH (885 mL), C4H9OH (100 mL),
AlCl36H2O (109g), ZnCl2 (250g), and distilled water (120mL). A 20 x 20 mm 316L
stainless steel sheet was used as a cathode. The distance between the electrodes was ~60
mm. The current was 0.45 A, corresponding to a voltage of ∼26–28 V, and the
temperature was ~21-23 °C. The duration of the procedure was ~90 s. Throughout the
course of electropolishing the solution was stirred with magnetic agitation to avoid
waviness and streaks on the surface. Prior to anodization, Zn discs and wires were
electropolished. The samples were submerged in 1L of 0.5 M (COOH)2. (COOH)2 was
selected as an electrolyte because of the oxalate ability to bind strongly to the metallic
surface, thus improving the substrate corrosion resistance28. Anodization occurred for 1
min at room temperature using a 316L stainless steel cathode. The power supply was set
to a current of ~4 A corresponding to a voltage of ~10V. During anodization, the
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electrolyte solution was constantly stirred with magnetic agitation to reduce the thickness
of the double layer at the metal–electrode interface to obtain uniform local current
densities on the Zn electrode. All samples were cleaned in an ultrasonically stirred
acetone bath for 3 min and in a 75% (v/v) ethanol bath for 5 min after each stage of
preparation.
3.2.2 Surface characterization
A FEI Philips XL 40 equipped with a tungsten filament and operated with an acceleration
voltage of 15 kV was used for scanning electron microscopy (SEM) analyses.
Micrographs were acquired with a probe current in the range of 1·10-10 to 1·10-8 mA. Xray photoelectron spectroscopy (XPS) characterization was carried out to determine the
chemical composition of the EP and AD surfaces (PHI 5800 spectrometer, Physical
Electronics U.S.A), with an incident angle of 45° with respect to the surface, and a
residual pressure of 5·10-9 Torr. A survey spectrum was recorded using a standard
magnesium X-ray source for survey spectra (0–1400 eV) at 400 W to identify all
elements present at the surface. High resolution spectra (HR) of C1s, O1s and Zn p3/2
regions were recorded with a standard Mg Kα X-ray source (1253.6 eV). The
spectrometer work function was adjusted to give 284.8 eV for the main C1s peak. Curve
fittings were determined using the Gaussian–Lorentzian (80–20) function and a Shirley
type background and performed using the software Multipack®. Each peak was
decomposed into Gaussian/Laurentian components, which have been attributed to the
presence of oxides, hydroxides, and carbonates/water. C 1s peak fitting was carried out
with following components: peak I C-C/C-H (~284.8 eV); peak II: -O-C=O- (~289.0 eV),
and peak III: carbonate groups and/or adsorbed CO and CO2 (~290.1 eV29-31). The
oxygen peak was composed of contributions located at: peak I: ~530 eV (oxide); peak II
~531.5 eV (hydroxide); peak III: ~533.5 eV (carboxyl groups, carbon dioxide and/or
adsorbed H2O31, 32). For Zn 2p3/2, the subsequent peaks were identified: peak I (~1021.8)
metallic zinc, peak II (~1022.) zinc oxide and peak III (~1022.7) zinc hydroxide and/or
carbonate.
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3.2.3 In vitro degradation behavior
The corrosion of EP and AD samples was studied in Hanks’ solution supplemented with
0.35g NaHCO3/L. The pH of the solution was adjusted to 7.4 using 1 M NaOH or HCl.
Open circuit potential (OCP), electrochemical impedance spectroscopy (EIS), and
potentiodynamic polarization tests were performed to study the corrosion behavior of the
investigated samples. The potentiodynamic test was performed using a conventional
three-electrode cell (Princeton Applied Research Model K47) with a platinum counter
electrode of 1 cm2 in surface area, a saturated calomel reference electrode and the
prepared Zn-based working electrode. The OCP vs the SCE RE was monitored without
applying any outside source for 3600s until equilibrium was reached at the corrosion
potential Ecorr. A scan rate of 0.166 mV/s, with an applied potential range of 1V, was
used. The experiments were carried in an aerated environment at 37±1°C. The solution
was stirred with magnetic agitation (80 rounds/min) during the test. For each type of
material, three specimens were tested using the same conditions. The electrodes were
connected to a potentiostat (PARSAT4000, Princeton Applied Research, PA, USA) and
monitored using the VersaStudio® software. The corrosion rates were obtained based on
the calculated corrosion current density (іcorr), using the following equation:
CR=3.27 ∙10‐3

icorr EW
ρ

(Eq. 1)

where CR is the corrosion rate (mm year-1), icorr is the corrosion current density (µA cm-2)
obtained on the base of potentiodynamic curves using Tafel extrapolation method, EW is
the weight equivalent and ρ is the material density (g cm-3).
Impedance spectra were separately collected from 100 kHz to 0.1 Hz with 5 mV
perturbation amplitude. Because of reactive nature of zinc, no data points were collected
below 0.1 Hz. The OCP potential was recorded for 30 min prior to the EIS measurement
to allow the interface to reach a steady state. EIS spectra were recorded after 1h, 24h,
72h, 120h and 168h. The results were adjusted according to equivalent electric circuits
using the software ZSimpWin®.
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For static immersion tests, the Zn-based discs with 0.8 cm2 exposed surface area were
immersed for 28 days in 40 mL of Hanks’ solution. The whole volume of solution was
changed every 7 days to keep the pH value close to 7.4 and to maintain conditions as
constant as possible. The containers were stored in a controlled temperature (T =
37±1°C), Three specimens were tested for each condition. The samples were
subsequently washed with 200 g L− 1 of chromium oxide in distilled water to remove
corrosion products. The surface morphologies and chemical compositions before
corrosion products removal were examined by SEM and energy dispersion spectrometry
(EDS).
3.2.4 In vivo wire implantation
Adult female Sprague Dawley rats were purchased from Harlan Laboratories. Nine
samples per treatment group were harvested over 2, 4, and 8 weeks (3 samples at each
time point), using a surgical procedure described previously33. At the euthanization time
point, the aorta containing the wire was dissected and excised, surrounded in polyfreeze
cryo medium, snap frozen in liquid nitrogen, and stored in a -80 centigrade freezer until
cryo-sectioning.
3.2.5 Tissue preparation, histological, and morphometric analysis
200x magnified H&E images were uploaded to MetaMorph image analysis software. The
thickest region of the neointimal growth was measured and recorded from cross sections
taken from at least three different locations along the wire, spanning approximately 0.2
mm. A detailed description of the methods for the morphometric analysis are described in
our previous publication33.
3.2.6 Statistical Analysis
All data was uploaded into MATLAB with a statistics machine learning toolbox package.
A Wilcoxon rank sum test was used to compare experimental groups. The lumen
occlusion index was used as a cutoff to exclude outliers (LOI  30%)33.
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3.3 Results
3.3.1 Surface characterization
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Fig.3-1. SEM micrographs of (a) EP and (b) AD samples, (c) Chemical
composition of EP and AD Zn surfaces by XPS and overlay of XPS high resolution
spectra and peak positions for (d) carbon – Cs1, (e) oxygen (O1s), (f) zinc (Zn
2p3/2) and (g) zinc auger (ZnLMM), (h) HR-XPS calculated values from the Gauss–
Lorentz fit for the O1s and Cs1 peaks.
SEM micrographs of the EP and AD surfaces are shown in Fig. 3-1. A smooth surface,
similar to the industry standard of bare metal biostable stents, is evident on degradable Zn
due to the EP process. In contrast, the Zn AD surface (Fig. 3-1b) is composed mainly of
prismatic particles (with sizes in the range of ~500-800 nm), similar in morphology to
what has been produced by other researchers following Zn anodization in oxalic acid 34,
35

. An ultra-thin oxide film (~4 nm) is formed on the EP surface (Fig. 3-2a), estimated

using an XPS depth profile. The AD coating is relatively uniform, ~6 µm thick, and
indicated by green two-headed arrow in Fig. 3-2c.
According to the XPS survey spectra, shown in Fig. 3-1c, Zn is present on both EP and
AD surfaces. Non-metallic elements such as C, N, and Cl were detected on the surface of
the both samples. Their presence is most likely a consequence of the surface preparation,
as EP and AD treatments involve the use of different acids and solvents. Fig. 3-1d-g
show the high-resolution scan data for C 1s, O 1s, Zn 2p3/2, and Zn LMM peaks. The
amount of oxygen on the surface is significantly higher for the AD sample, implying a
higher content of oxygen-containing compounds. Contamination from hydrocarbon
compounds was observed on both surfaces. Its source is constituents of the ambient air.
The presence of carbon has been observed on clean surfaces of most materials, even
under moderately high vacuum conditions36. These carbon species are not involved in
any chemical interaction with the underlying virgin surface species, as they are not very
reactive by their inherent chemical nature37. The content of carbon was lower for AD
samples as seen in Fig. 3-1c. In contrast, the air exposure of the EP surface resulted in
rapid accumulation of C containing compounds, because chemically evolving clean
metallic surfaces are more vulnerable to opportunistic carbon contamination37. The C1s
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HR spectra for EP samples reveal the main component as a C-C/C-H peak at 284.8 eV.
The AD surface treatment resulted in a carbon presence, with the main peak appearing at
a binding energy of 289.4eV. This peak can be divided into two components: C in the
carboxyl group (-O-C=O-) ascribed to Zn oxalate and/or carbonate groups and carbon at
290.1 eV. The peak at this binding energy is often reported as demonstrating evidence of
bonding between carboxylic groups and the metallic surface38-40. The XPS Zn
2p3/2 spectra for EP show a peak at 1021.5 eV, corresponding to Zn/ZnO. This peak has a
shoulder at higher binding energies, associated with the presence of Zn (OH)2 and/or
ZnCO3. However, only a single component is present on the AD surface, which can be
ascribed to zinc oxalate. The Zn Auger LMM peak revealed the presence of three peaks
for EP sample. These peaks are related to metallic zinc and were not clear in the case of
the AD surface. This might be due to the thicker zinc oxide film for the AD sample. The
HR-O1s peak of samples has been fitted with three peaks: O1s(1) at a binding energy of
531.5 eV assigned to Zn–O, O1 s(2) at a binding energy of 531.6 eV assigned to Zn–OH
and O1s (3) at a binding energy of 533.0 eV assigned to ZnC2O4/ZnCO2. An analysis of
the O1s spectra revealed an increase in Zn oxalate/carbonate for the AD sample relative
to EP. The quantified concentrations associated with the C, O and Zn peaks are presented
in Fig. 1h. Considering the complex nature of oxidation/precipitation on Zn surfaces, the
fitting of multiple Zn species is challenging. Unreliable interpretation can be produced
for the speciation of the Zn surface chemical state due to many possible Zn species with
overlapping binding energies.
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3.3.2 Corrosion behavior

Fig.3-2. The typical cross-sectional morphologies of EP (a, b) and AD (c, d) before and
after 28 days of exposure to Hanks’ solution, the surface morphologies of corroded EP
(e, f) and AD (g, h) before and after removing the corrosion products and EDS analyses
(i) corresponding to the points and areas highlighted on micrographs.
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In order to clarify the corrosion mechanisms, the influence of the surface treatment on the
polarization behavior of the AD and EP surfaces was investigated at 37˚C in Hanks’
solution by a morphological and chemical analysis before and after the corrosion
experiment. Fig. 3-2 shows typical surface morphologies and cross sections of noncorroded and corroded samples. Cross sectional observation of corroded EP samples (Fig.
3-2 a, b) revealed the formation of a porous, non-uniform film with varied thickness from
2 to 10 µm. In contrast, the porous AD coating (Fig. 3-2c) underwent densification during
the ongoing corrosion process. This may be due to blocked orifices in the anodic film
from Zn degradation products, which formed a relatively dense barrier during the 28 days
of exposure to Hanks’ solution (Fig. 3-2d).
The effect of the surface treatment on the corrosion behavior can be more clearly
assessed after removing degradation products. Signs of localized corrosion appear on the
EP surface (Fig. 3-2f). Only small pits were observed on AD surface, indicating a surface
attack that more than likely occurred during the deposition of the AD coating. EDS
analyses of the corrosion products (which are listed in Fig. 3-2i), revealed the presence of
Zn, Ca, P, O, Cl and Na. Hanks’ solution often produces degradation products that
contain zinc oxides, hydroxides, carbonates, calcium phosphates, and carbonates41, 42. The
oxygen content may imply the precipitation of oxides and insoluble hydroxides. This is a
result of the ionic reaction between Zn2+ and several acid radicals such
as Cl−, HCO3−, HPO42 −, which are components of the testing solution. Corrosion products
with atomic ratios of Zn:O close to 1:1 are consistent with zinc oxide, a 1:3 Zn:O ratio is
typical for zinc carbonate (ZnCO3). A ratio of Zn:O exceeding 2 might suggest the
presence of zinc hydroxide. Further, the presence of ZnC2O4 in anodic films (for samples
before and after corrosion) is confirmed by a 1:4 Zn:O ratio. Additionally, different Ca/P
ratios on the degraded surfaces were found. The Ca/P ratios of various calcium phosphate
salts are the following: 1 for CaHPO4(2H2O), 1.33 for octacalcium phosphate (OCP), 1.5
for tri-calcium phosphate (TCP) and 1.67 for hydroxyapatite (HA).
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The electrochemical measurements provided further insights into the corrosion behavior
of the surface treated samples. The respective polarization plots and their kinetic
parameters are shown in Fig. 3-3a. According to the data, EP samples showed a
minimum corrosion current density Icorr = 17.17 µA compared to AD Icorr = 20.12 µA. As
seen in Fig. 3a, the cathodic current densities of EP and AD samples are similar. The
anodic branches showed nearly the same trend. At potentials more positive than the Tafel
range, the current density plateau was established at approximately 10-1 A cm–2. The
anodic polarization curves of EP samples revealed a passivation-like region followed by
an acceleration to a higher dissolution rate (Fig 3a).
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Fig.3-3. Electrochemical measurement plots for AD and EP samples (a)
potentiodynamic polarization curves (b) Nyquist and (c) Bode plots for EP
samples, (d) Nyquist and (e) Bode plots for AD samples, after 1h, 24h, 72h,
120h, and 168h of immersion in Hanks’ solution

The evolution of the electrochemical behavior for the EP and AD was monitored by EIS
as a function of time. Nyquist and Bode diagrams for both types of zinc surfaces, EP and
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AD are presented in Fig. 3-3 (b-d) for periods of exposure corresponding to 1h, 24h, 72h,
120h, and 168h. It is important to note that for 168 hours of exposure the impedances
associated to the AD samples were superior to these of the EP substrate. Further, the
results revealed that between 1 and 168 hours there was a large increase in the impedance
of the AD samples (from ~250 Ω·cm2 to ~900 Ω·cm2, Fig. 3d), while that of the EP
slightly decreased after 24 hours, reaching finally the value ~400 Ω·cm2 after 168 h (Fig.
3-3b). The results of the potentiodynamic tests refers to the sample surfaces after 1h of
exposure to the Hanks’ solution. Accordingly, the results of EIS showed lower corrosion
resistances for AD samples after 1h compared to EP (Fig. 3-3b, d). After 1h of exposure,
a time constant to frequencies of around 10 kHz is observed, likely due to charge transfer
processes and charging of the double layer at the Zn surface and underneath the pores in
the AD film. For 24 hours of exposure, the indication of another time constant at low
frequencies associated to corrosion processes at the metallic substrate is seen on the
Nyquist diagram (Fig. 3-3 b). This could be explained by the localized corrosion of the
EP substrate and the formation of corrosion film. When comparing Bode plots of EP (Fig.
3-3c) and AD (Fig. 3-3e), both curves in impedance and phase angle plots of anodic
coating showed a shift to a lower frequency. The AD Bode diagram corresponding to 168
hours of immersion test show a shoulder at frequencies around 1 kHz and a peak at 1 Hz
indicating a stable surface after the increasing dissolution of AD coating (Fig 3-3 e).
Additionally, the part of AD coating under the influence of corrosive medium
transformed into Zn-based oxides/carbonates/phosphates featuring low solubility and
acting as a corrosion barrier. To quantify the changes in the impedance for EP and AD
samples, the results presented in Fig. 3-3 were fitted using a circuit electric equivalent
embedded in Nyquist plot (Fig. 3-3 b, d). The model providing an adequate fit of the EP
data is shown in Fig 3-3b (inset). The EP/solution interface is interpreted as bi-layered
corrosion product, made of an inner (Ri, Qi) and an outer (Ro, Qo) layer. The Ri and Ro of
EP displayed decreasing corrosion resistance within 24 h, then increased gradually to 120
h and decreased again afterwards 43-46. Both the capacitance and the resistance of the
outer layer are high and the ƞ value indicate a non-perfect interface (0.7–0.9) (Table S1,
supplementary materials), which can be attributed to a hydrated
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oxide/carbonate/phosphate layer. Ri and Ro decrease after the first 24 h, indicating the
disruption of the EP surface due to the corrosion attack. After 72h, the increase in
resistance is observed suggesting the growth of the degradation products. The low Qi
values after immersion times of 1 h, 24 h and 72 h are typical for porous films. Increasing
Qi after 120 h, suggest the formation of more stable, dense corrosion products layer.
Accordingly, the corrosion resistance increases with degradation products formation and
their accumulation on the EP sample surface. The high frequency arc on Nyquist plot was
assigned to the charge transfer process, whereas the low frequency arc was allotted to the
formation of unevenly distributed Zn corrosion products and species adsorbed on EP
surface. The equivalent circuit depicted in Fig. 3-3d was used to fit spectra of AD sample.
Rsol was the solution resistance, Rct and Qdl represented the resistance of charge transfer
and capacitance of the electrical double layer; Q (constant phase element) was used here
in place of a capacitor to compensate for the non-homogeneity of the system46, 47. The
AD film became homogeneous in terms of defects distribution, with lower number of
micro-pores resulting in reduced roughness (and the actual surface area of the coating)
leading to a decrease in Rsol. The Rct value increases with progressing corrosion,
suggesting the densification of the AD film. The diffusion resistance can be mainly
attributed to the inner, denser layer of the coating. The reduction in Qct (reflecting the
nature of the inner layer structure) comes from the thickening of the double layer,
suggesting that corrosion products are formed at the surface/electrolyte interface. The rise
of Rsol and Rct indicates the formation of a compact layer on the AD surface, and charge
transfer reactions in the protective film, respectively, resulting in the densification of the
AD layer and the homogenized, more corrosion resistant surface structure. The solution
resistance (Rsol) remained relatively stable during the entire experiment and the
reproducibility was good for all three samples.
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3.3.3

Histomorphometry and biocompatibility

A representative image of the neointimal tissue that formed around the implants is shown
for each condition in Fig.3-4. Thin, non-protruding neointima is observed for the AD
implants, with a variable response to the EP implants.

Fig.3-4. H&E staining depicting typical (top row) and deleterious responses
(bottom row)
The following equation was used to obtain the lumen occlusion index of a sample33,

LOI= [

WLT

(Eq. 2):

] ×100%

BNL‐Φ

The lumen occlusion index (LOI), where WLT is the wire to lumen thickness, BNL is the
base neointimal length (in micrometers), and Φ is the wire diameter (in micrometers).
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Fig.3-5. Quantification of in vivo histomorphometric analysis. Boxplots show the
average with the boxed region ranging from 25% - 75%. Whiskers extend from
0% - 100% with each dot representing one sample point.
While there were neither failures nor reductions in biocompatibility (BC) for any of the 9
AD treated samples, the EP condition produced 1 failure based on lack of
endothelialization, 2 failures based on LOI, and 2 reductions in BC, as shown in Fig.5.
The reductions in BC are defined as any neointimas with a LOI ≥ 20% and ≤ 30%33.
Failures are defined as any samples with LOI of 30%. The quantified
histomorphometric analysis is shown in Fig. 3-5. One EP sample was excluded from the
statistical analysis due to a lack of endothelialization. With this exclusion, no statistical
difference between WLT (45µm  12µm vs 99µm  100µm), BNL (813µm  262µm vs
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604µm  105µm) or NA ((6 + 8)×104 vs (8 + 5)×104) is observed. There is no difference
between the two groups in terms of LOI (10 + 5% vs 33  37%), although there is a trend
towards significance (p=0.118).

3.4 Discussion
Although a degradable surface film is designed to rupture and eventually dissolve, it
serves as the initial interface between the medical implant and biological environment. In
this central position, the surface film regulates the host response and potentially direct
long-term neointimal remodeling. Although the degradation products of zinc implants
have been shown to inhibit harmful neointimal responses48, the surface film
characteristics necessary to achieve optimal suppressive effects have not been explored in
the scientific literature. Here, we have developed surface films through electropolishing
and anodization processes with different characteristics to test the hypothesis that the
surface film character of degradable zinc implants regulates neointimal responses. The
character of AD and EP zinc surfaces was described based on surface features, corroded
surface morphologies, cross sectional study, and electrochemical analyses. AD and EP
surfaces prepared on Zn wires were then implanted into the abdominal aorta of Sprague
Dawley rats for a direct comparison in terms of fundamental biocompatibility metrics.
We successfully prepared a smooth and defect-free surface (EP), similar to industry
standard stents manufactured for clinical use. In marked contrast, the AD surface was
rougher, with a bumpy nano-scale pattern and a thickness of about ~6 µm (Fig. 3-2c).
The AD surface possessed a higher atomic percentage of oxygen and carbon, with
potentially a presence of zinc carbonate and oxalate. In contrast, an ultra-thin oxide film
was present on the EP sample. After in vitro corrosion, a porous corrosion layer was
present on the EP sample, while a densified corrosion layer was recorded on the AD
sample (Fig.3-2b, 2d). After removal of the corrosion products, large areas of localized
corrosion were observed on the EP surface, while only small defects were visible on the
AD surface that are ascribed to the surface attack during anodization process (Fig. 3-2f,
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2h). Although the EP and AD surfaces possessed similar corrosion potential values with
similar corrosion rates (Fig.3-3a), the anodic region of the EP curve on Fig.3-3a displays
a tendency towards dissolution when compared to AD, revealing a slight passivation of
the AD surface. The AD surface was resistant to corrosion overall, as shown by the
initially high impedance values on the comparable Nyquist plots (Fig.3-3b, 3d) and the
densified corrosion layer that formed on the AD sample. In contrast, the Nyquist and
Bode plots of the EP condition revealed inferior corrosion resistance. Indeed, the
development of localized corrosion was confirmed from the 28-day immersion in Hanks’
solution (Fig.3-2f).
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Fig.3-6. Schematic illustration of corrosion process of AD and EP samples.
The contributions of the prepared surface films to the corrosion behavior of the Zn
materials can be described based on the presented in vitro pre and post corrosion analysis.
With increasing exposure time, the reaction mechanism for carbonates, phosphates, and
hydroxides is significantly slower, and mutual diffusion from the Zn substrate and
Hanks’ solution is reduced. Principal diffusion pathways are provided by the capillaries
in the porous corrosion layers (and anodic film in the case of AD samples, Fig.3-6),
where Zn ions diffuse from the bulk material toward the solution/surface interface. Ions
present in the body fluid diffuse in the opposite direction (shown in Fig. 3-6). Thus, the
degradation rates are reduced with corrosion product thickening and its densification.
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The surface oxide-hydroxide-phosphate-carbonate film on AD and EP samples cycle
through a process of partial dissolution and re-precipitation in Hanks’ solution. When the
dissolution rate is larger than that of re-precipitation, ions are gradually released. When
the metallic surfaces are covered with a thick and compact film, the corrosion resistance
increases. However, the composition of this protective film might change even though
these precipitates are macroscopically stable. The AD samples exhibited a higher
corrosion resistance compared to EP, during longer exposure to Hanks’ solution as shown
by EIS measurements (Fig. 3-3). The Zn degradation precipitates blocked pores and
capillaries in the AD film, protecting the Zn metal during longer exposures to
physiological solution. In contrast, the protective film formed on EP samples was less
compact, with varied thickness. Thus, it provided limited corrosion protection.
Since the noted differences in surface films influence corrosion behavior, we asked
whether the different oxide film characteristics could provoke changes in the
biocompatibility of zinc implants in the abdominal aorta of rats. Based on nine
observations per treatment group, the AD surface produced stable, non-obstructing
neointimal growth, while the EP preparations evoked a high rate of harmful responses
(Fig. 3-4). Specifically, we observed two reductions in biocompatibility for the EP
condition, and two outright failures in terms of LOI 30% (Fig.3-5). Another failure of
one EP specimen was due to lack of endothelialization. The lack of roughness in the EP
preparation vs. AD may explain the delay in endothelialization, as 3-dimensional surface
features may aid in cell adhesion and migration49, 50. In total, three out of the nine
observations failed for the EP condition, and an additional two had a reduction in
biocompatibility. In contrast, the nine AD specimens were free from failures or
reductions in biocompatibility.
When evaluating the biocompatibility of vascular materials that are destined for human
use, the numerical clustering of the BC metrics is an important consideration, even when
the average response is acceptable from an application standpoint. The large spread in the
tabulated data for the wire to lumen thickness (WLT) and lumen occlusion index (LOI)
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for EP specimens raises serious concerns, as it suggests that the in vivo response is nonuniform. The variability in biocompatibility responses could be a consequence of the
non-uniform in- vitro corrosion behavior. Critically, corrosion product stability is reduced
on the EP surface, leading to localized corrosion and pitting. The increase in substrate
attack (apparent in Fig. 3-2) caused by a porous, loosely compacted corrosion layer that
aids in solute diffusion to the metal-product interface could promote localized sites of
inflammation along the wire that initiate neointimal growth and smooth muscle cell
proliferation. Thus, increased variability from localized corrosion due to surface film
character directly translates to impaired in vivo performance. Overall, the EP condition
increased variability in the WLT metric, and produced a near significant increase in the
LOI (p=0.118). The EP surface produced a 22% failure rate based on the LOI exclusion
criteria (2 out of 9), with only 44% of the observations meeting the full biocompatibility
benchmarks (4 out of 9). 100% of the AD samples (9 out of 9) met the full
biocompatibility benchmarks, leading to a failure rate of 0 % (0 out of 9). To provide
context with clinical observations of stent performance, bare metal stents incur a
restenosis (failure) rate of between 20%-30%, with drug eluting stents reducing this value
to <10%. Using the restenosis rate of present generation drug eluting stents (~10%) as a
guideline, the AD surface is seen as potentially improving outcomes while the EP surface
falls outside expectations for success. Although the AD coating employed here may not
be appropriate for stents due to potential cracking of the layer during balloon crimping
and deployment, this investigation highlights the critical importance of oxide films for
determining the biocompatibility of degradable zinc metal implants.

3.5 Conclusions
An electropolished and anodized surface oxide film with widely varying characteristics
were prepared on degradable zinc implants and compared, both in vitro and in vivo, to
clarify the relationship between surface film properties and biocompatibility. The
following conclusions were reached:
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The anodized samples exhibited a higher corrosion resistance compared to
electropolished during longer exposure to the physiological solution due to the
densification of the oxalate film, which acted as a barrier limiting the contact of the
substrate with electrolyte.
The corrosion product film formed on electropolished samples was less compact, with
varied thickness. Thus, it provided limited corrosion protection.
The electropolishing produced a smooth and thin oxide film surface that elicited a high
variability in biocompatibility, with a high rate of failure, possibly due to surface
corrosion heterogeneity.
In contrast, the corrosion stability of the anodized surface film corresponded to improved
biocompatibility outcomes.
In particular, the ability to tune the in vivo biodegradation behavior and biocompatibility
of the Zn biomaterial as a function of surface properties was experimentally verified
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4 In-Vivo Biocompatibility of Next Generation Zn-Ag
Based Stent Materials 7
4.1 Introduction
Since the introduction of zinc as a degradable metallic candidate for bioresorbable stents
in 2013[1], numerous zinc alloy formulations with improved mechanical properties and
microstructure relative to pure zinc have been investigated [2-5]. A central feature of the
zinc-based stent materials being developed is their gradual degradation in the arterial
environment, until their eventual disappearance [6, 7]. The biodegradable feature of zincbased materials makes them highly interactive with the host environment. Although
bioresorbable implants differ considerably from conventional biostable implants in terms
of their interaction with the host, most studies provide limited details regarding the
biological effects evoked by the implant’s presence and degradation. Consequently, there
remains a wide deficit in our understanding of the impact of alloying elements and bulk
processing on the tissue response to zinc-based implants. The biointeractivity of zincbased materials needs to be thoroughly characterized in order to engineer zinc-based
implants with improved safety and efficacy relative to their bioinert metallic counterparts.
Our group has worked to clarify the relationship between the material composition,
properties and surface finish of degrading zinc implants and the biologic responses they
evoke in the arterial environment [8-15]. We make use of an implant model wherein a
wire made of the material in question is implanted into the abdominal aorta of healthy
Sprague Dawley rats and allowed to degrade for 3-20 months[9, 12, 13]. Recently, we
developed a histomorphometric approach to quantify the performance of bioresorbable
materials in the arterial environment [11]. This work has identified thresholds that
distinguish between acceptable materials and those that stimulate a harmful smooth
muscle cell proliferative response, a hallmark failure of long-term implanted stents.

7

Material in this chapter is in preparation to be submitted to a journal for publication
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Of all the zinc-based implants evaluated so far, pure zinc generally evokes the most
favorable response within the vascular environment. A stable neointima forms around
pure zinc that is restricted in terms of area, thickness, and progression and generally
avoids inflammatory infiltrates for up to 11 months. We recently reported that alloying
with magnesium contributes to the biological failure of zinc implants through excessive
tissue growth [11]. Although the implantation of a Zn-4Li alloys into the arterial
environment did not produce outright failures, this alloy experienced a reduced
biocompatibility metric relative to pure zinc due to an increased degree of inflammation.
In addition to modifications to the bulk matrix, we have also shown that the initial surface
oxide film characteristics dramatically affect the early neointimal growth [9][16]. For
instance, thin surface oxide films produced by conventional electropolishing are
susceptible to large variations in corrosive attack that lead to excessive variations in
biological responses[9]. In contrast, relative stability of the surface oxide film (imparted
for example through anodization) promotes a more homogenous corrosion along the
length of the wire, which results in more positive and reproducible biological responses.
In contrast to some success seen in modifications of the surface[9, 16], manipulating the
bulk metal through alloying to improve the mechanical properties has tended to reduce
the overall biocompatibility of the implant material relative to pure zinc.
As metallurgical modifications continue to advance and alloy compositions become more
complex, it has become more urgent to clarify the relationship between material
characteristics and tissue response. Such clarifications may provide predictive power for
metallurgists to aid in the design of zinc-based medical implants. More recent zinc
systems include 2-4 alloying elements to refine the grain structure, increase
microstructural stability, and improve the mechanical properties of zinc to acceptable
levels for stenting applications [2, 4]. The addition of each element impacts corrosion
behavior and products, secondary phases within the microstructure, and surface
characteristic, all of which can affect the overall device biocompatibility at various stages
after implantation. A deeper understanding of the relationships between material
modifications and biological responses is needed to identify desirable material
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characteristics from a biocompatibility standpoint, providing a foundation for
metallurgical engineering of bioresorbable medical alloys.
Recently, a new Zn alloy system has been introduced with the addition of Ag[17]. This
system benefits from an increased volume fraction of AgZn3 particles that precipitate at
the grain boundary and provide grain boundary strengthening due to impaired
propagation of dislocation slip plains, as well as increased grain refinement (grain size
1.5 m)[18]. The Ag addition dramatically increases the ultimate tensile strength to 280290 MPa without sacrificing elongation to failure, and provides a beneficial antibacterial
effect [2, 18].
Here we leverage high sample sizes to investigate the biocompatibility of 3 novel Zn
based Ag-containing alloys, ranging from binary to quinary alloy systems. This work was
intended to clarify the relationship between elemental profile and biocompatibility for the
Zn-Ag system. Selected binary and quinary Zn-Ag-based alloys underwent thermal
treatment (TT) to increase the solubility of Ag-rich phases within the Zn bulk matrix,
yielding 2 different microstructures with the same elemental composition. A side-by-side
comparison of implant materials with and without TT was intended to clarify the effect of
microstructural features on biocompatibility. The insight gained from these experiments
is needed in order to integrate biological considerations into the metallurgical design of
fine/ultrafine-grained structure Zn-based materials through alloying and processing.

4.2 Methods
4.2.1 Alloy Formulation
High-purity starting metals (>99.99%) were melted at 700°C in a sealed cylindrical
graphite crucible in an electric resistance furnace to minimize oxidation and ensure that
sound castings are produced. The ingots had a cylindrical shape with a nominal diameter
of 28 mm and a length of 100 mm. The bars were machined to a nominal diameter of 25
mm and homogenized for 8 hours at approximately 400°C followed by water quenching.
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Nominal elemental formulations were used as outlined below:
Zn-4Ag (wt%)

(binary)

Zn-4Ag-0.6Mn (wt%)

(ternary)

Zn-4Ag-0.8Cu-0.6Mn-0.15Zr (wt%) (quinary)
The homogenized alloys were subsequently extruded at 310°C with an extrusion rate and
speed of 39:1 and 0.5 mm/min, respectively, to obtain cylindrical rods with a diameter of
4 mm. The extruded rods were cold drawn at Fort Wayne Metals (Fort Wayne, IN) to a
wire with a diameter of 0.25 mm.
The binary and quinary alloys were heat treated in order to minimize the Ag-rich
precipitates. For the binary alloy, TT was performed at 360°C for 10s, while the quinary
alloy, due to its multiplicity of alloying elements, required higher temperature and
soaking time (390°C for 20 min).
4.2.2 TEM preparation
Transmission electron microscopy (TEM) samples were prepared using standard routes,
including grinding and polishing the wires to < 40 mm in thickness followed by ion beam
milling to electron transparency. Low angle-ion beam milling was performed at liquid
nitrogen temperature by a GATAN precision ion polishing (PIPS) II using Ar+initially at
5 keV and final milling at 1 keV. TEM data were obtained with JEOL JEM F200
transmission electron microscopy operating at 200 kV.
4.2.3 Implantation and collection
Implantations, implant retrieval, and histological processing were performed as
previously described [11]. Wires were implanted into female Sprague Dawley rats for 6
months. Sixteen samples were produced for each material.
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4.2.4 Statistical analysis
All data was tabulated in Excel 2016 and uploaded to MATLAB 2016Ra. Raw data was
transformed into log space for statistical comparisons. An unpaired two sample Welch’s t
test was used to investigate the experimental groups. When appropriate, an F test was
used to identify differences in the variance. All data was approximately normal.

4.3 Results and Discussion:
4.3.1 Microstructural Characterization

Fig. 4-1. (a, b) TEM images of as-drawn binary and quinary alloys, (c, d) their
corresponding EDS elemental
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Fig. 4-1 shows the transmission electron microscopy (TEM) images of the binary and
quinary alloys before and after the thermal treatments. It can be clearly seen form Fig. 41a and b that for both alloys the wire drawing results in the formation of an ultrafinegrained (UFG) structure (grain size of 600 nm and 200nm for binary and ternary alloys,
respectively). Formulated alloys underwent tensile testing and microstructure analysis.
However, because mechanical properties of alloys are irrelevant to biocompatibility study
they will be presented in a separate publication. Only selected mechanical data are provided
in this section to guide general correlations between microstructure and mechanical
properties of the alloys.
Fig. 4-1 shows the transmission electron microscopy (TEM) images of the binary and
quinary alloys before and after the thermal treatments. For both alloys the wire drawing
resulted in the formation of an ultrafine-grained (UFG) structure with grain size of 600 nm
and 200nm for binary and ternary alloys, respectively (Fig. 4-1a&b). An EDS elemental
map of the as-drawn binary alloy wire demonstrates the formation of submicron
deformation induced-AgZn3 precipitates within a size range of 100 nm - 500 nm (red
particles) uniformly dispersed in the Zn matrix (Fig. 4-1c). The formation of these
precipitates markedly enhances the ductility such that the material exhibits exceptional
room temperature superplasticity (fracture elongation > 400%). However, this
superplasticity is accompanied by a remarkable loss of mechanical strength (~ 73%). In the
case of the quinary alloy (Fig. 4-1b and d) the considerably smaller grain size relative to
the binary alloy (200 nm vs 600 nm) is attributed to the extremely refined and uniformly
dispersed MnZr-rich particles. Such particles hinder the growth of the newly recrystallized
UFG grains during the drawing process, resulting in markedly smaller grain size. The EDS
elemental map of the quinary alloy shows that the addition of Cu appreciably decreases the
fraction of AgZn3 precipitates (Fig. 4-1d). This results in a lower fracture elongation of the
quinary relative to the binary alloy (90% vs 430%). To restore the mechanical properties,
thermal treatments were carried out on the as-drawn alloys. Fig. 4-1e shows that for the
binary alloy, TT at 360°C for 10s leads to dissolution of a large number of the AgZn3
precipitates as well as a significant grain growth. In fact, the remarkable decrease in the
112

volume fraction of AgZn3 precipitates in TT binary alloy could restore almost 73% of the
mechanical strength. In the case of the quinary alloy, TT was conducted at a significantly
higher temperature and for a longer soaking time (390˚C, which corresponds to 96% of the
alloy’s melting point, for 20 min). Fig. 4-1f reveals that, surprisingly, despite the very high
temperature, only a small grain growth occurs (from 200 nm to 2.4 µm). This is attributed
to the greatly fine and uniformly distributed MnZr-rich intermetallic particles at grain
boundaries, which are outstandingly thermally stable, that prevent grain coarsening even
at high temperatures. Indeed, the TT quinary alloy could substantially restore its
mechanical strength (around 84%) while exhibiting a high fracture elongation of 32%.
4.3.2 General Histologic Presentation

Fig.4-2. Representative H&E and VVG stains of the binary, ternary, and quinary
alloys. The neointima is outlined in yellow to increase clarity. Scale bar is
approximately 500 m
The general histological presentation of the tested alloys is shown in Fig. 4-2. Typical
binary Zn-4Ag, ternary Zn-4Ag-0.6Mn, and quinary Zn-4Ag-0.8Cu-0.6Mn-0.15Zr
implants are shown with H&E and VVG stains. H&E staining is ideal for microscopic
cell identification and characterization of the general tissue reaction, while the VVG
technique clearly differentiates elastic lamina fibers and neointimal tissue. Since we are
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mainly concerned with the macro neointimal development around each implanted alloy,
the VVG stain is primarily used for ease of histomorphometric measurements.
The binary and ternary alloys display excessive neointmal thickness and area, with the
quinary alloy showing a reduced, ideal neointimal type at 6 months. The binary and
ternary alloys show evidence of increased inflammation within the neointima, by H&E
identification of inflammatory cells (not shown). This was largely absent for the quinary
alloy, with a reduced cell density and stable neointima growth that does not appear to be
progressive.
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4.3.3 Effects of alloying

Fig.4-3. Boxplots of Pure Zn, copper-free alloys, and Cu containing alloys for
histomorphometrics. Panels A and B show comparisons using a Welch’s two
sample t test. Panels C and D show comparisons of the variance with a two
sample F test.
The effects of alloying and processing on the in vivo performance of degradable zinc
materials was compared in terms of histomorphometry parameters, using an approach
previously described [11]. Fig. 4-3 shows a high sample size pooled performance of
alloys implanted from 3-12 months, including pure zinc, multiple copper-free alloy
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systems (Zn-4Ag, Zn-4Ag-0.6Mn, Zn-4Li, and Zn-XMg [0.1,0.001,0.001wt%]), and the
Zn-4Ag-0.8Cu-0.6Mn-0.15Zr alloy developed by our group. In vivo performance was
quantified by neointimal thickness (WLT) and neointmal area (NA). Interestingly, a
similar WLT was found between the copper-free alloys and the quinary system relative to
pure zinc (Fig. 4-3A). However, there is a clear superior performance of the coppercontaining quinary alloys relative to the copper-free alloys, (P=0.000019).
The copper-free alloys generally incur a reduced biocompatibility relative to pure Zn in
terms of NA, with a higher sample mean (P=0.0016). The NA for the copper-containing
alloy is significantly reduced relative to the copper-free alloys (P=0.0000000035), and
even improved over that of pure zinc. We attribute the reduction in NA to a reduced
inflammation at the interface of the Cu containing alloy (Fig. 4-2).
A previously described lumen occlusion index (LOI) was used to compare novel alloys in
terms of negative proliferative responses that occludes the lumen. Surprisingly, none of
the new alloys exceeded the biocompatibility limit LOI value of  30%, or the reduction
in compatibility limit LOI of or 20%. The excellent LOI values for the Zn-Ag alloys
may be due to their extended base neointimal length (BNL), along with typical WLT
values (which could indicate positive remodeling). Although none of the implants failed
outright, the large NA produced by the binary and ternary alloys is concerning. This large
increase in area is primarily due to an increase in inflammation, which is a well-known
contributor to negative stent outcomes. The LOI measurement does not take into account
NA, but rather relates to the protrusive growth of the neointima into the luminal space.
Our lab has found that a neointimal protrusion metric is generally related to smooth
muscle cell proliferation, while a large increase in NA is generally indicative of excessive
inflammation[11]. Both factors should be considered when gauging the biocompatibility
of degradable materials, especially since satisfactory performance on the LOI scale does
not demonstrate optimal performance in all histological metrics.
Sample variance between the experimental materials is a major consideration when
evaluating histological samples. Tighter data spread is associated with more uniform
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performance. This feature is especially valuable in the intra luminal environment, which
is subject to occlusion at any point along the length of the implant [9]. Pure zinc
generally exhibits an ideal histological variance, avoiding corrosion behavior that
provokes large changes in neointimal growth along the length of the implant. While there
are generally no differences in the variance of WLT between pure zinc implants and the
copper-free alloys, the copper-containing quinary alloys demonstrate a much tighter data
spread than copper-free alloys (P=0.029, Fig.4-3c). NA measurements for the copper-free
alloys are generally more variable relative to both pure Zn (P=0.0044) and coppercontaining alloys (P=0.0238). The quinary alloy and pure Zn exhibit a similar variance,
suggesting a more ideal performance from copper-containing alloys in terms of
generating consistent neointimal morphomety.
Elemental composition is a serious consideration when designing alloys. When the binary
Zn-Ag composition was alloyed with Mn, the biocompatibility (BC) was considerably
reduced. The BC then recovered following the addition of Zr and Cu. While it can be
difficult to isolate the effects of the Mn addition (which can alter corrosion behavior and
form new inter metallics), it is apparent from our results that changes in the elemental
profile of a degradable zinc implant can dramatically impact the BC.

117

4.3.4 Effects of nano-precipitate phases

Fig.4-4 Three representative VVG stained sections of the binary and quinary
alloys. High variability in neointimal size can be seen in both the binary and its
solution treated counterpart. A decrease in overall NA is seen in the quinary
alloy, with an even greater reduction in its solution treated counterpart. Scale bar
is approximately 500 m.
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In order to clarify the effects of nano-precipitate phases on neointimal growth, the binary
and quinary Zn-Ag alloys were thermally processed to dissolve the insoluble deformation
induced-AgZn3 nano-precipates. Applying TT has the benefit of reducing the amount of
precipitates and thereby restoring the mechanical strength of the alloy [19].
Fig.4-4 shows the in vivo performance of both as drawn and solution treated binary and
quinary alloys. For each alloy, three representative samples are depicted to demonstrate
typical responses of the alloy system. For the binary system, large sample-to-sample
differences are present in the NA (outlined in each image). The variability between
samples does not appear to change after solution treatment (Fig.4-4 second row). The
quinary system shows a marked reduction in NA relative to the binary system, along with
a decreased variance. Solution treatment of the quinary alloy further reduces the NA and
WLT, demonstrating the benefit of the solution treatment to biocompatibility.
The complete histomorphometric analysis of these samples is shown in Fig. 4-5. As
shown in Figs 4-5A and 4B, WLT (but not NA) slightly benefitted from the solution
treatment of the Zn-Ag binary alloy. The Zn-Ag and Zn-Ag TT materials both evoked an
increased inflammation relative to pure zinc, which we attribute to the presence of Ag
precipitates. It is well known that Ag nanoparticles contribute to inflammatory
phenotypes in macrophages and elicit direct cell toxicity [20, 21]. Therefore, a more
pronounced reduction in Ag precipitates (obtainable by increased treatment time or
temperature) may be beneficial in terms of biocompatibility.
The quinary alloy containing Ag and Cu possesses the same Ag nano precipates.
Interestingly, after thermal treatment of the Zn-Cu containing alloy, in vivo performance
was dramatically improved, and even superior to pure zinc. WLT (P=0.023) and NA
(P=0.000028) from the Zn-Cu-TT alloy readily outperforms pure zinc. It is interesting
that the solution treatment for the binary alloy did not improve the BC as dramatically as
for the quinary system. The solution treated binary alloy microstructure retains
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substantial Ag precipitates, possibly a consequence of the low ST time that was chosen in
order to optimize the mechanical properties. Although the untreated quinary alloy also
possesses Ag nano-precipitates, we speculate that the beneficial cellular effects from the
addition of Cu overwhelms the negative response that is generated from these harmful
phases.
Fig.4-5. Comparisons of the histomorphometric performance of binary Zn-Ag

and quinary Zn-Ag-Mn-Zr-Cu alloys in the as-drawn form and after solution heat
treatment. All comparisons were made with a two sample Welch’s t test.
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We are the first to report a zinc-based alloy (Zn-4Ag-0.8Cu-0.6Mn-0.15Zr (wt%)) that
performs better than pure zinc in terms of biocompatibility. We speculate that the Cu
inclusion has a beneficial impact on inflammatory development and neointimal growth.
Cu has been shown to increase the proliferation of endothelial cells, but not smooth
muscle cells [22]. In a proinflamatory environment such as a newly injured artery,
increased scavenging of reactive oxygen species could have a beneficial effect on
neointimal progression and inflammation. Cu can also directly act as a catalyst for the
generation of NO from endogenous RSNO’s, which could also inhibit inflammation [23]
and SMC growth [24]. Furthermore, increased superoxide dismutase (SOD) activity in
EC’s could promote a favorable balance towards additional NO release [25].

4.4 Conclusions
The findings of the study conclude:


Addition of alloying elements to zinc usually decreases the biocompatibility of
zinc implant in vascular environment by increasing inflammation responses;



Ag-rich nano-precipatites decrease biocompatibility, a phenomenon that can be
counteracted by dissolving the AgZn3 precipates in the bulk Zn matrix;



Cu addition to Zn-Ag alloy reduces inflammation and substantially increases
biocompatibility, even in the prescence of harmful AgZn3 precipitates, an effect
that is enhanced when the precipitates are dissolved in the Zn matrix; and



Neointimal forming cells are responsive to elemental additions and
microstructural changes in degradable zinc based materials.
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5 Zinc Based Materials Regulate the Vascular Biologic
Response to Implants by Releasing Therapeutic
Transition Metal Ions8
5.1 Introduction
Zinc (Zn) based degradable scaffolds under development for cardiovascular applications
have garnered increasing attention in recent years [1-5]. Metallurgical innovations that
increase the mechanical properties have positioned this class of degradable metals to
move forward in preclinical testing of stent prototypes [6]. However, while there has
been extensive research and development with regards to alloying and materials
refinement, the biological consequences of a degrading zinc-based arterial implant have
not been well addressed in both fundamental and clinical studies.
The concept of biodegradation is straightforward; physiological fluids break the material
down into byproducts that are either metabolized or cleared from the implant site. As the
implant degrades, the space occupied by the material is gradually infiltrated by cells and
matrix and reintegrated into the host environment. As with all implanted materials, the
initial cells arriving at the material-tissue interface are predominantly macrophages and
foreign body giant cells that help clear the implanted material [7]. For arterial implants,
smooth muscle cells (SMCs) eventually form a dominant cell type within a developing
neointima [8]. For materials that are designed to degrade, an added consideration beyond
the original material is the effect of degradation byproducts on the behavior of infiltrating
cells. Magnesium (Mg) alloys and polymers such as polylactic acid (PLLA) remain the
most widely studied materials for fully degradable stent devices in terms of the biological
action of byproducts. Magnesium degrades into Mg2+ ,Mg/O, and MgOH2, eventually
leaving behind a Ca/P rich product [9-11]. PLLA degrades by hydrolysis into nontoxic
biocompatible products [12]. Similar to the selection of bioinert metals for conventional

8
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biostable stents, a primary consideration behind selecting bioresorbable materials for
stenting has been to avoid negative biological responses. Indeed, Mg and PLLA
materials have advanced through pre-clinical studies and entered into clinical trials in
large part because their degradation byproducts do not interfere with the normal
functioning of the native surrounding cells and are highly unlikely to promote systemic
effects[11-13].
Because the byproducts of degradation can diffuse away from the implant interface,
clarifying the biological action of degradation byproducts on vascular smooth muscle
cells is of paramount importance. Early work with zinc uncovered LD50 values that were
well below that of Mg and Fe (iron) [14, 15]. This raised the prospect that ionic Zn might
exert a strongly toxic effect on arterial cells. However, the exact opposite way of
thinking was suggested by early in vivo findings. Low inflammation, the absence of any
overt signs of necrosis, and a stable neointima predominated around Zn implanted into rat
arteries out to ~6 months[16]. Based on the in vitro findings, one would have expected to
see a strong inflammatory response, the clear presence of necrotic regions, and a negative
neointimal progression. Together, the in vitro and in vivo findings suggest that the
biological effects of zinc on neointimal progression may not be mediated by toxicity, but
rather by programmed intracellular signaling pathways.
Due to zinc’s inherently low mechanical properties, a Zn stent material requires the
addition of alloying elements[1-5]. Alloying of zinc with non-toxic elements at their
specified concentrations can be used to improve mechanical properties and refine
microstructure of the implant. If an element exerts beneficial bioactive effects on arterial
cells, its incorporation into the bulk matrix ensures its elution as the implant degradation
progresses. In such a manner, an advanced bioresorbable stent metal can be engineered
to release multiple beneficial bioactive elements at optimized concentrations for the
lifetime of the implant. Alloying with copper, for instance, can improve the structural
and mechanical properties of zinc implants[17]. In this communication, we introduce a
new concept of using Zn2+ and Cu2+ ions as potential therapeutic elutants that are
supplied to a host site from degradable zinc-based implant.
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5.2 Experimental
5.2.1 Materials
ACS reagent grade methanol was purchased from Millipore Sigma (St. Louis, MO).
Bradford assay kit (ab102535), caspase-3,caspase-8 and caspase-9 multiplex activity
assay kit fluorometric (ab219915), TUNEL assay kit (ab206386), anti-cleaved caspase-3
antibody (ab2302), anti-alpha smooth muscle actin antibody (ab5694), and goat antirabbit IgG Alexa Fuor 488 were all purchased from Abcam (Cambridge, MA). 4’,6Diamidino-2-phenylindole dihydrochloride (DAPI) (D8417), Dulbecco’s modified
eagles medium-low glucose (DMEM) (D6046), Dulbecco’s phosphate buffered saline
(PBS) (D8662), penicillin-streptomycin (P4333), goat serum (G9023), zinc acetate
(383317), D-glucose(G8270), and fetal bovine serum (F2442) were purchased from
Sigma-Aldrich ( St. Louis, MO). 3-morpholin-4-ylpropane-1-sulfonic acid
(MOPS)(172630250) was purchased from Fisher Scientific ( Toronto, ON). High purity
Zn wires (4N-99.99wt%) were purchased from Goodfellow (Coraopolis, PA) Platinum
wires were purchased from Fort Wayne Metals (IN).
5.2.2 Methods
In vivo Implantation
Pure zinc (Zn) and platinum (Pt) wires were implanted into the abdominal aorta of adult
female Sprague Dawley rats for 3 months, n=5. A detailed description of the surgical
procedure was provided in our earlier publication [18]. The wire and tissue explants were
collected, surrounded by optimal cutting media, and snap frozen in liquid N2. The
samples were stored at -80oC until cryo-sectioning.
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General Histology, immunofluorescence and in-situ apoptosis detection
Wire/tissue samples were cross-sectioned with a cryo-microtome at 10 µm section
thickness and placed on histobond glass slides. Multiple sections spanning a ~0.2 mm
distance were collected for each sample. For hematoxylin and eosin staining (H&E) and
TUNEL labeling, sections were fixed in paraformaldehyde for 10 min. H&E staining was
carried out by protocols described by the authors previously [18, 19], and TUNEL
labeling was performed following manufactures’ protocols.
For immunofluorescence, sections were fixed in ice cold methanol for 5 min and allowed
to air dry before washing. The slides were rinsed 3X in PBS, then blocked in a 10% (v/v)
goat serum solution in PBS for 30 min. After blocking, slides were either incubated with
an anti-cleaved caspase-3 antibody (1/100 dilution) overnight at 4 oC, or an anti- smooth
muscle alpha actin antibody (1/250 dilution) for 1 hr at room temperature (RT). After
incubation, the slides were rinsed 3x with PBS and incubated with goat anti-rabbit IgG
Alexa fluor 488 (1/300 dilution) for 1 hr at RT. The secondary solution was rinsed with
PBS 3x, then stained with a DAPI solution (1/1000 dilution of 1mg/mL stock) for 2 min
at RT. DAPI was rinsed off with PBS and the slides were mounted with a glass coverslip
and aqueous mounting media, and imaged immediately with an upright BX51 Olympus
epifluorescence microscope.
Ex-vivo arterial ring tissue culture
In order to investigate the potential of Zn2+ to activate caspase-3 in smooth muscle cells
directly, an ex vivo arterial culture model was developed. The thoracic aorta was
collected from donor adult female Sprague Dawley rats. Each thoracic aorta was cut into
rings of approximately 5-8 mm in length in Dulbeco’s PBS supplemented with 1%
penicillin-streptomycin (PS) (v/v). The arterial rings were randomized and allowed to
recover overnight in low glucose DMEM supplemented with 10% FBS and 1% PS, at 5%
CO2 and 37oC. After overnight recovery (to allow cells to adjust to culture conditions and
recover from injury), the arterial rings were randomly immersed in a physiological saline
solution (131 mM NaCl, 4 mM KCl, 2.5 mM CaCl2, 5.5 mM glucose, and 1 mM MgCl2)
128

buffered by 10 mM MOPS at a pH of 7.25 (pH adjusted with sodium hydroxide), or the
same physiological saline solution with the addition of 0.5 mM Zn acetate, MgCl2, FeCl3,
or CuCl3. The arterial rings were incubated in the control and insult loaded saline
solutions for 12 hours.
After incubation, the smooth muscle cell containing media compartment was
mechanically separated from the other arterial compartments. The adventitia
compartment for each arterial ring was bluntly dissected from the media layer using
forceps under a stereomicroscope. Removal of the endothelial cells was confirmed with
en-face DAPI imaging (not shown), and the media layer was immediately washed in PBS
containing no magnesium and calcium and stored in lysis buffer at -80oC for further
processing.
Multi-caspase activity assay
Caspase-3, caspase-8, and caspase-9 activity was detected for the media compartment of
the arterial rings using a plate based fluorescent assay. The compartment was
homogenized in a lysis buffer provided by the manufacturer, and protein determination
was carried out using a Bradford assay kit. The multiplex caspase activity kit (abcam
ab219915) provides each substrate used to detect its respective caspase in a conjugated
form to fluorophores with wide spectral separation, allowing multi-caspase activity to be
determined in the same lysate. There was a minimum of 4 samples per condition (n=4).
Confocal microscopy
Confocal microscopy was used to inspect the in situ localization of active caspase-3
within the zinc-insulted arterial segments. After collection, thoracic aortas were allowed
to recover in supplemented DMEM overnight at 37oC. The segments were then rinsed in
PBS and incubated in either a 0.5 mM zinc solution or control saline solution. The
segments were then rinsed in PBS, surrounded by optimal cutting medium and snap
frozen in liquid N2. 50 m thick cryosections were taken at five evenly spaced locations.
These sections were stained for active caspase-3 as described above, imaging three
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locations per section with an Olympus FluoViewTM FV1000 laser scanning confocal
microscope. 30 m volume stacks were taken for each 600x magnified field.
Corrosion of alloys and ICP-OES analysis
Ternary Zn-4Ag-0.6Mn and quinary Zn-4Ag-0.8Cu-0.6Mn-0.15Zr ultrafine zinc wires
were corroded in Hanks balanced salt solution [20] for 14 and 28 days. The solutions
supernatant were then sterile filtered with a 0.22 µm syringe filter. After filtration, the
solutions were acid digested with trace metal basis nitric acid, and analyzed using
inductively coupled optical emission spectroscopy (ICP-OES). The detection limit for
copper is 10 ppb.
Statistical Methods
An unpaired two sample student’s t test with unequal variance was used to evaluate
experimental groups. Error bars are given as sample standard error. A minimum of 4
sample replicates (n=4) was included for all experimental groups. A one-way ANOVA
was used to compare multiple groups.
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5.3 Results
5.3.1 Morphometric presentation

Fig.5-1 General histomorphometry and neointimal cellularization of Pt and Zn
The typical appearance of the neointimas (NI) that developed on Zn and Pt wires
is shown in Fig.5-1. H&E staining at 100x normal magnification depicts thin,
continuous NI formation over both wires. In order to compare the cellularity of
the NI produced by the two materials, DAPI staining was performed, as shown in
the bottom two panels of Fig.1. Both NIs appear to be cellularized with a similar
spatial distribution of cells. Furthermore, histomorphometric parameters,
including NI area for Pt vs. Zn, (5. 4 ± 1.6)×104 μm2 vs. (6.6± 1.9)×104 μm2 and
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wire to lumen thickness (50 ± 12 µm vs. 59 ± 21 µm) show a slight but nonsignificant elevation for Zn (p=0.308 and p=0.433, for area and thickness,
respectively) (n=5 per condition).
5.3.2 TUNEL labeling of NI and -SM / active caspase-3 presence
Cross sections of the Pt and Zn implants were labeled for TUNEL+ identification. The Pt
specimens displayed low TUNEL+ staining in both the luminal and mural regions of the
NI. In stark contrast, all Zn specimens demonstrated strong TUNEL+ staining within
both the mural and luminal portions of the NI. When taken as a percentage of area
covered by threshold analysis, the NI surrounding Zn implants was significantly more
TUNEL+ (2.4 ± 2.1% vs 6.5 ± 1.5%, p=0.008, Pt n=5 vs Zn n=5, respectively).
In addition to higher TUNEL+ staining within the NI surrounding Zn implants, we
observed a reduced amount of α-SMA area coverage in Zn NI tissue compared to the
platinum control (23 ± 2% vs 14 ± 6%, p=0.017, Pt vs Zn, respectively). This reduced
amount of α-SMA area coverage for Zn specimens was associated with an increased
amount of area coverage in the NI for active caspase-3 (4.3 ± 2.7% vs. 8.6 ± 2.0%,
p=0.032, Pt n=5 vs Zn n=4 respectively).
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Fig.5-2 Neointima cellular and protein expression of Pt and Zn. TUNEL, alpha
smooth muscle actin, active caspase 3 and DAPI staining were performed for a
minimum 3 sections per sample (n=5 samples per condition). Data error is
reported in standard sample error and statistical significance is shown by a
Welch’s T test. Scale bar is set at approximately 100µm.
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5.3.3 Dose dependent caspase -3, -8, and -9 activation by Zn
In order to determine whether Zn may promote caspase activation in smooth muscle cells,
we incubated arterial segments in multiple concentrations of Zn for 12 hours, ex vivo. We
found that smooth muscle cell caspase-9 is not activated by 0.5 mM Zn (Fig 5-3a).
Interestingly, higher Zn concentrations significantly suppress caspase-9 activity from
basal levels (1 mM and 1.5 mM, p<0.00005). An increase in caspase-8 activity is
detected at 0.5 mM relative to the control condition, Fig.5-3b (p<0.0005). Higher
concentrations of zinc significantly inhibit caspase-8 relative to the 0.5 mM condition (1
mM and 1.5mM, p<0.00005). Caspase-3 activity was significantly elevated at all
treatment conditions (Fig.3c, p<0.05 at 0.5 mM, p<0.0005 at 1 mM, and p<0.005 at 1.5
mM) relative to the control group. Activity significantly increased from 0.5 mM to 1 mM
and from 0.5 mM to 1.5 mM (p<0.05). Therefore caspase-3 activity was not suppressed
by any of the zinc concentrations evaluated.
5.3.4 Effect of transition metal ions on caspase activity
In order to investigate whether the transition metal ions of common degradable metals
stimulate caspase activity at excess concentration, we performed activity assays with
arteries that were incubated in 0.5 mM solutions of either Fe, Mg, or Zn. Zn elicits the
strongest increase of caspase-3 activity as compared to Mg and Fe transition metal ions
(Fig.5-3.D, p<0.0005).
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Fig.5-3 Caspase activation in the ex vivo arterial culture system. Caspase -9 (A),
-8(B), and -3(C) activity in 3 different concentrations is shown. Caspase-3
activation in 500µM Fe, Mg, and Zn is shown in (D). E and F represent confocal
images from control and Zn treatment groups respectfully of active caspase 3
staining present in cross-sections. Data error is presented in sample standard
error and *=p<0.05,**p<0.005,***p<0.0005, and ****p<0.00005.
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5.3.5 Addition of Cu to bulk zinc materials
A promising Zn material alloyed with copper (Cu) was selected to evaluate the potential
biological effect of its eluted Cu constituent on caspase activity. Fig.5-4 shows the
neointimal response to Zn-4Ag-0.6Mn, and Zn-4Ag-0.8Cu-0.6Mn-0.15Zr alloy wires
implanted within the abdominal aorta for up to 6 months. The mural (Fig.5-4a) and
luminal (Fig.5-4b) portions of Zn-4Ag-0.6Mn wire neointimas (outlined by the blue
arrows) failed to endothelialize . In contrast, a stable endothelium is clearly seen for the
Zn-4Ag-0.8Cu-0.6Mn-0.15Zr wires (Fig.5-4C and D - identified by the red arrows).
ICP analysis in Fig. 5-4E shows the elemental profile of in vitro corrosion fluid for the
two respective alloys at 14 and 28 days. Significant Cu release can be seen for the Cucontaining alloy, with no Cu release for the Cu-free control (red line denotes detection
limit for the ICP system to Cu). The ICP results demonstrate the release of Cu ions into
the corrosion fluid from the Cu-containing alloy. To evaluate whether Cu could induce
caspase activity, we incubated arterial segments in 5 µM and 50 µM Cu solutions for 12
hours and probed for caspase-3 activity. Neither condition elicited significant caspase
activity within smooth muscle cells, indicative of caspase-independent mechanisms of
biologic interaction.
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Fig.5-4 Copper addition in advance zinc alloys effects the vascular response
through non caspase dependent pathways. A and B show mural and luminal
600X normal magnification H&E images of Zn-4Ag-0.6Mn wires at 6 months
within the abdominal aorta. Blue arrows depict inflamed endothelium. C and D
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show luminal and mural views Zn-4Ag-0.8Cu-0.6Mn-0.15Zr wires at 6 months in
histological cross-section. Red arrows show confluent, non-inflamed endothelium. E
shows ICP analysis of corrosion media

5.4 Discussion
The present study explored the similarities and differences between the neointimas that
develop around degradable (zinc) and non-degradable (platinum) implant metals. From a
histomorphometric perspective, platinum and zinc materials placed into healthy murine
arteries form neointimas with similar characteristics (Fig.5-1). From a broad view, the
similar cell densities, neointimal area, and neointimal thickness measurements
demonstrate the promise for use of zinc-based metals as vascular implants.
Materials selected in the past to serve as stents, either as biostable or bioresorbable
materials, are intended to be highly bioinert in order to avoid interaction with local and
systemic systems. Although these materials perform superbly when tested in healthy
animal arteries, they often fail to prevent progressive intimal hyperplasia and restenosis
when deployed into the atherogenic environment of diseased human arteries. The
limitations of this approach have necessitated the incorporation of drug-eluting coatings,
in an effort to impart suppressive properties to bioinert stent materials.
Here we show that zinc ions elution from metallic zinc platforms potently suppresses
neo-intimal hyperplasia of smooth muscle cells (SMCs), widely recognized as the
primary cause of failure for stented human arteries [21-23]. We have recently reported on
the promising in vivo behavior of metallic zinc implants in the abdominal aorta of
Sprague Dawley rats, out to 6 months [16]. Confluent endothelialization was found along
the luminal surface of the stable neointima, with a decreasing gradient of smooth muscle
cells (SMCs) close to the implant surface [16]. Based on these preliminary observations,
we hypothesized that the byproducts of zinc corrosion may exert suppressive effects on
arterial SMCs. The present findings implicating caspase enzymatic activity and apoptosis
signaling pathways in mediating the suppressive effects strongly suggest that the
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response to ionic zinc is programmed, rather than a response to injury. If zinc ions were
toxic to SMCs, we would have observed inflammation, necrosis, and progressive intimal
hyperplasia.
Zinc is a well-known inhibitor of caspase-3, 8, and 9 activity when evaluated in
concentrations exceeding 100 µM [24-26]. Although this inhibitory effect has been
described extensively in literature using cell-free systems [26], the relationship between
excess zinc and caspase enzymatic activity using intact cell systems is less clear. For
instance, it has been shown that excess zinc at high concentrations can provoke mixed
forms of cell death in cancer cell lines, mediated by caspase cascade activation [27] .
However, studies focusing on the effects excess zinc in vascular smooth muscle cells is
relatively lacking. Because the concentration of zinc is expected to be high directly at
the interface of a zinc-based implant, we sought to measure caspase activity in neointimal
cells at the interface of zinc wires implanted into the arterial environment and in arterial
media layers cultured ex vivo in simulated high zinc environments.
Caspases 3 and 8, but not 9 become significantly elevated in high concentration zinc
conditions, as shown by Fig.5-3. Surprisingly, at concentrations of zinc exceeding 0.5
mM, caspases 8 and 9 dramatically decrease in activity relative to both the control and
0.5 mM conditions. Conversely, caspase-3 continues to increase in activity with zinc
concentration, consistent with the extensive apoptosis we have detected in the neointimas
of zinc wires. This is also not surprising, as caspase-3 is the most robust caspase in
respect to inhibition of the proteolytic activity, requiring 1 mM for complete inhibition of
the enzyme [26]. Caspase-9 is known to be potently inhibited by zinc [24], which could
explain its lack of activation in the lower concentration condition and suppressed activity
at the higher zinc levels. Caspase-8 may also be inhibited in some manner at high
concentrations of ionic zinc. The data suggests a complex interplay of caspase activation
and zinc concentration, which ultimately yields caspase-3 activation and apoptosis
execution.
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We also found an anti-inflammatory effect from the added elution of copper ions, which
significantly reduced neointimal thickness and inflammation around the implant. This
effect is independent of the caspase-3 induced activation of zinc, as shown in Fig.5-4f. It
has been reported that both Zn2+ and Cu2+ can stimulate NO release from endogenous and
synthetic S-nitrosothiols (RSNOs) [28-30]. We recently reported that the amount of NO
released by Cu2+ from the synthetic RSNO, SNAP, was an order of magnitude higher
than that of Zn2+[31]. Free endogenous RSNOs circulate in the blood and are constantly
replenishing [32], providing a continuous source of NO generation for degradable
materials that elute Zn2+ and/or Cu2+. Local NO production from the release of Cu2+ from
biodegradable materials in addition to Zn2+ may improve the biological response, owing
to the critical physiological roles of NO in regulating vascular function. Beneficial
effects of NO include inhibition of platelet aggregation [33], leukocyte adhesion [34, 35],
and vascular SMC proliferation [36], all contributing factors to the restenosis of stented
arteries. Interestingly, it has been shown in peripheral blood mononuclear cells that zinc
protects against copper induced DNA damage, and substantially raises the LD50 value of
copper [37]. Copper also increases the proliferation rate of endothelial cells, but not
SMC’s [38].Fig.5-4 nicely shows a confluent, endothelium that is largely lacking in the
inflammatory ridden ternary alloy.
The present findings have major implications for the future of bioresorbable stent
development. Drug eluting polymer coated stents (DES) have become the main approach
for the revascularization of occluded coronary arteries. These stents combine mechanical
scaffolding with the release of pharmaceutical agents from a polymer coating on the stent
surface that act to inhibit smooth muscle cell proliferation [39]. Although second
generation DES have reduced the rates of late stage thrombosis relative to bare metal
stents (BMS) [39], these stents still experience a ~10% incidence of in-stent restenosis
(ISR) [40]. Furthermore, ISR for DES begins after 6 – 9 months and increases up to 2
years following implantation, as opposed to peaking between 3 – 6 months for BMS [40,
41]. The time course suggests limitations related to the drug in addition to the inherent
limitations of permanent stents. For instance, the drug release time course is limited to
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several months. Of potentially major importance when considering drug safety,
paclitaxel has recently been shown to sharply increase the risk of death many years after
stent deployment, likely due to systemic side effects [42]. It is an open question whether
other commonly used drugs for stent elution elicit similar systemic effects.
Recognized limitations with DESs have given rise to the concept of fully bioresorbable
polymeric scaffolds (BRS), which are in ongoing development to replace their permanent
metallic counterparts [43]. This feature is expected to restore positive arterial remodeling
while removing sources of thrombogenesis, inflammation, and neointimal activation.
However, all the polymers that have been selected for scaffolding exhibit substantially
reduced mechanical properties relative to metals, necessitating thicker struts. This
worsens malapposition, reduces endothelial regeneration, and leads to an increased risk
of thrombosis [43]. Bioresorbable metallic alternatives are further behind in
development, yet with appropriate modification can achieve similar mechanical
properties as conventional stent metals and have achieved some preliminary success [43].
Unfortunately, Fe and Mg based scaffolds will require drug eluting polymer coatings
when deployed into small diameter arteries.
Due to the limitations of anti-proliferative eluting drugs, the development of a
bioresorbable metallic stent that does not require synthetic drug elution is urgently
needed. In marked contrast to what has been shown previously for Fe and Mg , we have
shown here that the byproducts of zinc implant biocorrosion suppress the harmful
activities of neo-intimal smooth muscle cells. Zn2+ and Cu2+, like Mg2+ and Fe2+, are
present in the body naturally and the low quantities released from a stent that biodegrades
over a year, in particular with copper included as a low concentration alloying addition,
are unlikely to substantially alter their systemic levels. Thus, Zn2+ and Cu2+ may act in a
similar fashion as synthetic eluting drugs to protect against intimal hyperplasia of smooth
muscle cells, yet for a longer duration and without the harmful systemic side effects of
synthetic drugs. We propose, consequently, that the development of bioresorbable
metallic zinc stents could proceed without polymer coatings or synthetic drug elution.
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5.5 Conclusions
In the present paradigm, byproducts of implant degradation are seen largely as systemic
pollutants to be cleansed from the body without promoting toxic effects. We propose a
new paradigm, wherein the appropriate degradation byproducts are seen as therapeutic
agents, similar to the synthetic drugs impregnated into modern day drug-eluting stents,
yet naturally found in the body. Due to the physiological presence of the element, an
elevated local concentration can be achieved to deliver therapy near the implant without
promoting systemic effects. It is straightforward to embed multiple components within
the zinc matrix and control their concentrations through conventional alloying
approaches. Such an approach would serve both to improve the structural and
mechanical properties of the material and to elute multiple therapeutic agents into the
local environment.
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6 Concluding Remarks
This work illuminates the complex interplay between degrading zinc-based implant
materials and the vascular environment. Current simplistic conceptualizations of the
foreign body response must be reconsidered when examining degradable materials. The
field of biomaterials has witnessed a fevered introduction of degradable materials over
the past 20 years, including metals, polymers, composites, additively manufactured
matrices, and natural substrates. With the addition of zinc as a new class of biomaterials,
our understanding of how the innate and adaptive immune systems interact with
implanted materials must evolve. In the body of evidence provided in chapter 1, we have
shown that the inflammatory response is capable of accommodating degrading zinc
materials. Identifying links between cellular driving forces that increase corrosion
activity and vice versa could allow for formulating a theoretical foundation that further
enhances our abilities to engineer advanced degradable biomaterials.
When designing zinc-based biomaterials for cardiovascular use, it is imperative to
observe the material in the “application environment”. Conventional 2-D cell culture
methodology does not provide meaningful insight when applied to materials intended to
operate in the complex environment of the intraluminal arterial space. Conversely,
manufacturing of stents and implantation in pig models is prohibitively expensive. To
bridge the gap, we developed a simple and effective methodology to accelerate the
invention of novel degradable biomaterials and accomplish their screening based on their
quantified performance in a realistic experimental rat model. Using this approach,
presented in detail in chapter 2, material characteristics in a wire implant geometry can be
described in terms of their contribution to neointimal growth. To explore this approach,
the author evaluated different surfaces with varied surface oxide layer stability
engineered on zinc substrates, presented in chapter 3. The reduction in biocompatibility
for one of the surfaces was related to a relatively low surface oxide stability that
increased susceptibility for pitting corrosion. We found that pitting corrosion vs. uniform
corrosion leads to localized bursts of zinc corrosion, producing in turn a highly localized
inflammatory reaction that worsens neointimal growth. This led us to conceptualize the
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engineering of zinc implants with a “tunable” neointimal response by controlling the
surface oxide film stability. Taken together, the chapter illustrates how relating material
characteristics to the micro cellular and macro tissue development provides fundamental
insight into the neointimal responses, which in turn can impact the metallurgical
engineering of the material.
In addition to exploring relationships between material properties and biological
responses, the framework of testing that we developed in chapter 2 can be applied to the
purpose of identifying the best performing materials fabricated by our research group. By
statistical comparisons of biocompatibility metrics using high sample sizes, we have
identified the quinary alloy (Zn-4Ag-0.8Cu-0.6Mn-0.15Zr) as the best performing
material, following solution treatment to maximize mechanical properties. This is the first
alloyed zinc material that performs better than pure zinc. The identification of this alloy
is described in detail in chapter 4. The mechanisms by which this material generates
outstanding biological responses is clarified in chapter 5 and summarized as follows:
I - the addition of Cu reduces inflammation and increases endothelilaization
II - the provocation of inflammation by AgZn3 precipitates is decreased by solution
treatment
III - zinc and copper exert a synergistic effect to suppress neointimal growth
In chapter 5, the author begins to clarify the mechanisms by which zinc based degradable
materials may suppress neointimal growth. When the neointimal development around
platinum and zinc wires was compared, there was a reduced smooth muscle cell presence
and an increased cellular apoptosis in the zinc neointima. The author hypothesized that
the release of Zn2+ from degrading zinc-based implants induces programmed cell death,
or apoptosis, of smooth muscle cells. The role of Zn2+ was confirmed by exposing arterial
smooth muscle cells to high concentrations of Zn2+, ex vivo, in order to isolate the effects
of ionic zinc from variables related to implant materials. The activity of the executioner
caspase (3) was found to be elevated in high zinc conditions. This controlled form of cell
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death is beneficial to a progressively developing neointima, as it would shift the deathproliferation balance to stabilize against the progressive growth that eventually occludes
stented arteries. This is an extremely important discovery since the proliferation of
smooth muscle cells represents the hallmark mode of failure for arterial stents.
In summation, the work begins with the development of a new methodology to
qualitatively and quantitatively evaluate the in vivo biocompatibility of degradable
implant metals. This methodology was used to relate material characteristics to
biological responses, including surface oxide film character, alloying composition, and
bulk processing conditions. In addition to generating insights into fundamental
relationships between materials and biocompatibility, the approach can be used to rank
materials in terms of biocompatibility. From this approach, beneficial alloying elements
and processing conditions can be identified. Beneficial elements identified by these
approaches can be further investigated for their therapeutic value in the form of transition
metals, since all the elements in the implant will be released due to biocorrosive activity.
Future studies will need to explore important questions that were generated by the present
work. The present work evaluates materials in a normal, healthy animal system. While
necessary to clarify fundamental relationships between material characteristics and
neointimal formation and begin to clarify mechanisms of suppression by ionic zinc, a
diseased arterial environment is more representative of the clinical environment. In
contrast to a healthy artery, the diseased atherosclerotic environment is pro-inflammatory,
more complex and unique per individual, and lipid laden. The performance of degradable
zinc materials will need to be evaluated in a dynamic and pro-inflammatory microenvironment. The most suitable modeling systems for arterial disease have been
developed decades ago by molecular biologists, using transgenic mice. It should be
possible to adapt the implant surgery and our quantitative morphometric approach to the
mouse. Positive performance of degradable zinc-based materials in diseased arteries
would increase confidence in the successful clinical translation of materials selected
using the approaches described in the present dissertation.
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A

Appendix for Chapter 1

Fig. 1-S1. Quantification of CD163 staining using average pixel counting of
multiple tissue sections per sample.
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Fig. 1-S2. Quantification of CD11b/c staining using average pixel counting of
multiple tissue sections per sample.
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Fig. 1-S3. In depth clarification for Fig. 2. Yellow arrows in panel A show
mononuclear cells. Cyan asterisk in C show region of compact corrosion product
with no nuclear staining. Red asterisk in D depict region of necrosis. Scale bar is set
to 100µm.
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Fig. 1-S4. Second clarification of Fig. 2. Red asterisk in E show necrotic regions,
yellow arrow displays a representative normal nuclear morphology, and the
green arrows depict representative abnormal nuclear morphology. Red arrows in
F identify thick, circumferentially aligned collagenous fibers, while in panels G
and H show a distinct collagenous capsule. Blue asterisks in panel G identify
chronic inflammation outside of the capsule, while in panel H they identify the
chronic inflammation both inside and outside the capsule. Scale bar is set at
100µm.
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Fig. 1-S5. Red asterisks for the SHG explant at 1.5 and 3 months show large
amounts of corrosion product. Yellow arrows show representative viable
mononuclear cells. The red line for the bottom two panels depict the original
border of corrosion pocket, with the red arrows showing the direction of cellular
penetration. Light blue arrow in bottom right panel shows a representative
region of pyknosis and karyorrhexis. Scale bar is at 100µm
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Fig. 1-S6. Yellow arrows in top left panel show representative mononuclear
cells, while the red arrows in the top right panel portray the cellular movement
from the original tissue - corrosion product border inwards towards the corroding
implant. The green arrows in the bottom panels show neovascularization, and
the cyan arrows identify representative fibroblasts. The yellow asterisks in the
2Al 4.5month panel shows corrosion product impregnated with cell nuclei. The
red circles in the bottom right panel show sites of macrophage fusion. Scale bar
is set at 100µm.
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Fig. 1-S7. Cyan arrows in the 4-Al 3 month panel show representative mature
fibroblasts at the interface. Red asterisks show representative inflammatory
cells. Green arrows in the bottom right panel show neovascularization. Yellow
arrows depict aligning fibroblasts. Scale bar is set at 100µm.
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Fig. 1-S8. Yellow arrows in the top left panel show acellular collagenous
bundles, with the red circle identifying representative dying inflammatory cells
within the corrosion layer. The 4-Al 6 month panel’s red asterisks show a thick,
acellular collagenous capsule, with the red oval identifying inflammatory cells.
The cyan arrows in the Zn-8Al 3.5 and 6 month panels identify the fibrous
capsule. The scale bar is set at 100µm.
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Fig. 1-S9. The top left panel’s yellow arrows identify representative large
mononuclear cells. In the 1.5 month SHG panel, the green arrows identify
representative intact cells, while the red circles identify characteristic piknosis
and karyorrhexis. The green arrows in the 6 month 4N panel also show viable
cells, while the red circles show areas of cell death. In the 6 month SHG panel,
the white oval shows a region incorporating both viable and non-viable nuclei
(green and red arrows respectively). Scale bar is set to 100µm.
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Fig. 1-S10. Yellow arrows in 1.5-month 2-Al panel identify cells of normal
nuclear morphology. Green circles of all panels show highly irregular nucleic
features with increased DAPI strength. Red circles show areas void of cell nuclei.
Scale bar is set at 100µm
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Appendix for Chapter 3

Table 3-S1. Fitting parameters of EP and AD samples after different immersion times

EP

AD

Time

Rsol (ohm·cm2)

Qi (μF)

η

Ri
(ohm·cm2)

Qo (μF)

ηo

Ro
(ohm·cm2)

1

15.64

0.34

0.81

176

177.34

0.78

270

24

14.54

1.12

0.73

40.54

268.10

0.97

180

72

15.93

1.59

0.95

120.8

238.15

0.75

324

120

17.7

8.75

0.95

165

920

0.75

374

168

16.48

7.09

0.78

139

854

0.92

305

Time

Rsol (ohm·cm2)

Qdl (μF)

η

Rdl
(ohm·cm2)

Qct (μF)

ηct

Rct
(ohm·cm2)

1h

15.74

62.21

0.98

168.58

110.78

0.81

129.40

24h

14.88

51.25

0.83

192.30

90.20

0.61

190.80

72h

12.55

51.4

0.77

471.36

95.05

0.92

245.10

120h

12.08

51.50

0.84

578.60

52.04

0.93

533.30

168h

12.48

45.74

0.95

349.02

38.31

0.81

788.20
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